US9974855B2 - Humanized anti-CD40 antibodies and methods of administering thereof - Google Patents

Humanized anti-CD40 antibodies and methods of administering thereof Download PDF

Info

Publication number
US9974855B2
US9974855B2 US15/829,352 US201715829352A US9974855B2 US 9974855 B2 US9974855 B2 US 9974855B2 US 201715829352 A US201715829352 A US 201715829352A US 9974855 B2 US9974855 B2 US 9974855B2
Authority
US
United States
Prior art keywords
antibody
binding portion
antigen
antibodies
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
US15/829,352
Other languages
English (en)
Other versions
US20180078640A1 (en
Inventor
Bo Yu
Rijian Wang
Keith REIMANN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Primatope Therapeutics Inc
Original Assignee
Primatope Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Primatope Therapeutics Inc filed Critical Primatope Therapeutics Inc
Priority to US15/829,352 priority Critical patent/US9974855B2/en
Publication of US20180078640A1 publication Critical patent/US20180078640A1/en
Assigned to PRIMATOPE THERAPEUTICS INC. reassignment PRIMATOPE THERAPEUTICS INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: REIMANN, Keith, WANG, RIJIAN, YU, BO
Priority to US15/955,393 priority patent/US10201608B2/en
Application granted granted Critical
Publication of US9974855B2 publication Critical patent/US9974855B2/en
Priority to US16/234,110 priority patent/US10772958B2/en
Priority to US16/994,249 priority patent/US11439706B2/en
Priority to US17/818,188 priority patent/US20220387587A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the invention relates to humanized anti-CD40 antibodies and uses of such antibodies, for example, to reduce the likelihood of, or treat, transplant rejection, to induce immunosuppression, or to treat an autoimmune disorder.
  • Organ transplantation has emerged as a preferred method of treatment for many forms of life-threatening diseases that involve organ damage.
  • transplantation rejection may occur when an organism receiving transplanted cells or tissue mounts an undesired immune response to that tissue. Transplant rejection may be minimized by tissue-type matching, but even matched tissue can be rejected by the donor.
  • immunosuppressive therapies are now used for virtually all cases of tissue transplantation.
  • CD40/CD154 interaction One potential target for reducing transplantation rejection is the CD40/CD154 interaction.
  • CD40 is expressed primarily on the surface of B lymphocytes and other antigen-presenting cells (APCs) such as dendritic cells and macrophages.
  • APCs antigen-presenting cells
  • CD154 is expressed primarily on the surface of T cells. The interaction between these two proteins is associated with B cell activation, which triggers cytokine expression as well as expression of cell surface markers including CD23, CD80, and CD86.
  • Kehry M. R CD40-mediated signaling in B cells. Balancing cell survival, growth, and death. J. Immunol. 1996 156: 2345-2348. Blockade of this interaction using anti-CD154 antibodies has been shown to reduce or eliminate rejection of transplanted tissues in non-human primates.
  • the present disclosure provides for a humanized anti-CD40 antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region, wherein the heavy chain variable region comprises three CDRs, CDR1, CDR2 and CDR3, having amino acid sequences about 80% to about 100% identical to the amino acid sequences set forth in SEQ ID NOs: 13, 14 and 15, respectively.
  • the present disclosure also provides for a humanized anti-CD40 antibody, or an antigen-binding portion thereof, comprising a light chain variable region, wherein the light chain variable region comprises three CDRs, CDR1, CDR2 and CDR3, having amino acid sequences about 80% to about 100% identical to the amino acid sequences set forth in SEQ ID NOs: 16, 17 and 18, respectively.
  • a humanized anti-CD40 antibody or an antigen-binding portion thereof, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises three complementarity determining regions (CDRs), CDR1, CDR2 and CDR3, having amino acid sequences about 80% to about 100% identical to the amino acid sequences set forth in SEQ ID NOs: 13, 14 and 15, respectively, and wherein the light chain variable region comprises three CDRs, CDR1, CDR2 and CDR3, having amino acid sequences about 80% to about 100% identical to the amino acid sequences set forth in SEQ ID NOs: 16, 17 and 18, respectively.
  • CDRs complementarity determining regions
  • the present disclosure provides for a humanized anti-CD40 antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises an amino acid sequence about 80% to about 100% identical to any one of the amino acid sequences set forth in SEQ ID NOs: 11, 19, 20, 21, 24, 25 and 26.
  • the present disclosure provides for a humanized anti-CD40 antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region and a light chain variable region, wherein the light chain variable region comprises an amino acid sequence about 80% to about 100% identical to any one of the amino acid sequences set forth in SEQ ID NOs: 12, 22, 23, 27, 28 and 29.
  • the present disclosure provides for a humanized anti-CD40 antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises an amino acid sequence about 80% to about 100% identical to any one of the amino acid sequences set forth in SEQ ID NOs: 11, 19, 20, 21, 24, 25 and 26, and wherein the light chain variable region comprises an amino acid sequence about 80% to about 100% identical to any one of the amino acid sequences set forth in SEQ ID NOs: 12, 22, 23, 27, 28 and 29.
  • the present disclosure provides for a humanized anti-CD40 antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises an amino acid sequence about 80% to about 1.00% identical to any one of the amino acid sequences set forth in SEQ ID NOs: 19, 20 and 21, and wherein the light chain variable region comprises an amino acid sequence about 80% to about 100% identical to either of the amino acid sequences set forth in SEQ ID NOs: 22 and 23.
  • the present disclosure provides for a humanized anti-CD40 antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises an amino acid sequence about 80% to about 100% identical to any one of the amino acid sequences set forth in SEQ ID NOs: 24, 25 and 26, and wherein the light chain variable region comprises an amino acid sequence about 80% to about 100% identical to any one of the amino acid sequences set forth in SEQ ID NOs: 27, 28 and 29.
  • the present disclosure provides for a humanized anti-CD40 antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises an amino acid sequence about 80% to about 100% identical to the amino acid sequences set forth in SEQ ID NO: 21, and wherein the light chain variable region comprises an amino acid sequence about 80% to about 100% identical to the amino acid sequences set forth in SEQ ID NO: 23.
  • the dissociation constant (K D ) of the antibody, or antigen-binding portion thereof may be less than about 1 ⁇ 10 ⁇ 9 M, or less than about 1 ⁇ 10 ⁇ 8 M.
  • the present antibody or antigen-binding portion thereof may be: (a) a whole immunoglobulin molecule; (b) an scFv; (c) a Fab fragment; (d) an F(ab′)2; and/or (e) a disulfide linked Fv.
  • the present antibody or antigen-binding portion thereof may comprise at least one constant domain selected from: a) an IgG constant domain; and (b) an IgA constant domain.
  • the present antibody or antigen-binding portion thereof may comprise at least one human constant domain.
  • the present antibody or antigen-binding portion thereof may bind to CD40 extracellular domain.
  • the CD40 may be human or rhesus CD40.
  • the present antibody or antigen-binding portion thereof may block B lymphocyte activation by CD154-expressing Jurkat cells in vitro.
  • the present antibody or antigen-binding portion thereof may inhibit B lymphocyte CD23, CD80, or CD86 expression.
  • composition comprising the present antibody or antigen-binding portion thereof, and at least one pharmaceutically acceptable carrier.
  • the present disclosure provides for a polynucleotide encoding the present antibody or antigen-binding portion thereof.
  • the present disclosure provides for a vector comprising the present polynucleotide, and a cell comprising the vector.
  • the present disclosure provides for an isolated polypeptide comprising the present antibody or antigen-binding portion thereof.
  • Also encompassed by the present disclosure is a method of producing the present antibody or antigen-binding portion thereof.
  • the method may comprise the following steps: (a) culturing the present cells in culture medium under conditions wherein the polynucleotide encoding the present antibody or antigen-binding portion thereof is expressed, thereby producing at least one polypeptide comprising the antibody or antigen-binding portion thereof; and (b) recovering the polypeptide from the cells or culture medium.
  • the present disclosure also provides for a method of suppressing the immune system in a subject, comprising the step of administering to the subject an effective amount of the present antibody or antigen-binding portion thereof.
  • the present disclosure provides for a method of treating or treating prophylactically transplant rejection, or increasing the duration of time before transplant rejection occurs, in a subject in need thereof, the method comprising the step of administering to the subject an effective amount of the present antibody or antigen-binding portion thereof.
  • the present disclosure provides for a method of treating or treating prophylactically graft-versus-host disease in a subject in need thereof, the method comprising the step of administering to the subject an effective amount of the present antibody or antigen-binding portion thereof.
  • the present disclosure provides for a method of treating or treating prophylactically an autoimmune disorder in a subject in need thereof, the method comprising the step of administering to the subject an effective amount of the present antibody or antigen-binding portion thereof.
  • the subject may have received, or is in need of, an organ transplantation, and/or a tissue transplantation.
  • the organ may be a heart, kidney, lung, liver, pancreas, intestine, and thymus, or a portion thereof.
  • the tissue may be bone, tendon, cornea, skin, heart valve, vein, or bone marrow.
  • the subject may be a human or a mammal.
  • the administration may be commenced prior to the transplantation.
  • the administration may continue for at least one month following the transplantation.
  • the administration may continue for at least six months following the transplantation of the graft.
  • the autoimmune disorder may be associated with or caused by the presence of an autoantibody.
  • the autoimmune disorder may be systemic lupus erythematosus (SLE), CREST syndrome (calcinosis, Raynaud's syndrome, esophageal dysmotility, sclerodactyl, and telangiectasia), opsoclonus, inflammatory myopathy (e.g., polymyositis, dermatomyositis, and inclusion-body myositis), systemic scleroderma, primary biliary cirrhosis, celiac disease (e.g., gluten sensitive enteropathy), dermatitis herpetiformis, Miller-Fisher Syndrome, acute motor axonal neuropathy (AMAN), multifocal motor neuropathy with conduction block, autoimmune hepatitis, antiphospholipid syndrome, Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome, rheumatoid arthritis, chronic autoimmune hepatitis, scleromy
  • the autoimmune disorder may be pernicious anemia.
  • the autoimmune disorder may be polymyositis, dermatomyositis, multiple endocrine failure, Schmidt's syndrome, autoimmune uveitis, adrenalitis, thyroiditis, autoimmune thyroid disease, gastric atrophy, chronic hepatitis, lupoid hepatitis, atherosclerosis, presenile dementia, demyelinating diseases, subacute cutaneous lupus erythematosus, hypoparathyroidism, Dressler's syndrome, autoimmune thrombocytopenia, idiopathic thrombocytopenic purpura, hemolytic anemia, pemphigus vulgaris, pemphigus, alopecia arcata, pemphigoid, scleroderma, progressive systemic sclerosis, adult onset diabetes mellitus (e.g., type II diabetes), male and female autoimmune infertility, ankylosing spondolytis, ulcerative colitis, Crohn's disease, mixed connective tissue disease
  • the administration may be parenteral, intravenous, subcutaneous, intramuscular, transdermal, oral, topical, intrathecal, or local.
  • the present method may further comprise administration of an immunosuppressant within six months of the administration of the present antibody or antigen-binding portion thereof.
  • the immunosuppressant may be a calcineurin inhibitor, tacrolimus, an mTor inhibitor, fingolimod, myriocin, alemtuzumab, rituximab, an anti-CD4 monoclonal antibody, an anti-LFA1 monoclonal antibody, an anti-LFA3 monoclonal antibody, an anti-CD45 antibody, an anti-CD19 antibody, monabatacept, belatacept, indolyl-ASC; azathioprine, lymphocyte immune globulin and anti-thymocyte globulin [equine], mycophenolate mofetil, mycophenolate sodium, daclizumab, basiliximab, cyclophosphamide, prednisone, prednisolone, leflunomide, FK778, FK779, 15-deoxyspergualin, busulfan, fludarabine, methotrexate, 6-mercaptopurine, 15-de
  • the calcineurin inhibitor may be cyclosporin A or cyclosporine G.
  • the mTor inhibitor may be sirolimus, temsirolimus, zotarolimus, or everolimus.
  • the anti-CD45 antibody may be an anti-CD45RB antibody.
  • the immunosuppressant is belatacept.
  • the present antibody or antigen-binding portion thereof and the immunosuppressant may be administered within one month, or within one week, of each other.
  • FIG. 1 shows the variable regions from the heavy chain and the light chain of the 2C10 antibody.
  • the nucleotide sequence shown for the heavy chain includes a signal peptide (nucleotides 1-57; underlined) and the heavy chain variable sequence (nucleotides 58-396).
  • the corresponding amino acid sequence is shown below (SEQ ID NO:2), where amino acids 1-19 corresponding to the signal sequence (underlined) and amino acids 20-132 correspond to the heavy chain variable region.
  • the nucleotide sequence shown for the light chain includes a signal peptide (nucleotides 1-66; underlined) and the light chain variable sequence (nucleotides 67-384).
  • the corresponding amino acid sequence is shown below (SEQ ID NO:4), where amino acids 1-22 correspond to the signal peptide (underlined) and amino acids 23-128 correspond to the light chain variable region.
  • FIG. 2 a is a plot showing flow cytometry data confirming the binding of 2C10 to human and rhesus CD20+ B cells.
  • FIG. 2 b is a plot showing CD40 adsorption data from ELISA assays with varying concentrations of 2C10 to confirm the binding of 2C10 to human and rhesus CD40 as detected using goat anti-mouse IgG-HRP.
  • FIG. 3 is a graph showing the dose-dependent inhibition of CD154 binding to human B cells by 2C10. B cells were analyzed for CD154 binding by incubating with histidine-tagged soluble CD154 and analyzing for histidine expression. Results are representative of multiple repetitions of the experiment.
  • FIG. 4 is a schematic diagram and graphs showing the principle of the assay involving rhesus or human peripheral blood mononuclear cells (PBMCs) and Jurkat cells.
  • PBMCs peripheral blood mononuclear cells
  • FIG. 5 is a set of graphs showing CD23 expression in CD20 + cells taken from co-cultures of rhesus PBMCs and Jurkat cells in the presence of variable concentrations of 3A8, 5C8, or 2C10 antibodies.
  • FIG. 6 is a set of graphs showing CD86 expression in CD20 + cells taken from co-cultures of human PBMCs and Jurkat cells in the presence of variable concentrations of 3A8, 5C8, or 2C10 antibodies.
  • FIG. 7 is a set of graphs showing CD23 expression CD20 + cells from either human or rhesus PBMCs cultured without Jurkat cells in the presence of either the 3A8 or the 2C10 antibody.
  • FIG. 8 is a graph showing peripheral B cell count of rhesus macaques treated with mouse-rhesus chimeric forms of 2C10 engineered to contain either rhesus IgG1 (2C10R1) or IgG4 (2C10R4) heavy chain constant regions, and chimeric IgG1 forms of anti-CD40 3A8 (3A8R1) or anti-CD40 Chi220 (Chi220).
  • FIG. 9 is a graph showing T cell-dependent antibody responses in macaque monkeys treated with 2C10R1, 2C10R4, or 3A8R1 antibody. All animals were immunized with 4-hydroxy-3-nitrophenylacetyl-conjugated keyhole limpet hemocyanin (KLH) after the first antibody treatment.
  • KLH 4-hydroxy-3-nitrophenylacetyl-conjugated keyhole limpet hemocyanin
  • FIG. 10 is a diagram showing the standard macaque model of allogeneic islet transplantation. Diabetes was induced in macaque monkeys using streptozotocin. Diabetic monkeys were transplanted with allogeneic islets and immunosuppression initiated with basiliximab and sirolumus. Experimental animals received 2C10R4 treatment on days 0 and 7 post-transplantation.
  • FIG. 11 a is a plot showing free blood glucose levels (FBG) in 4 macaques following islet transplantation, background immunosuppression, and treatment with 2C10R4.
  • the solid line on the plot represents the level of 2C10 in the plasma.
  • FIG. 11 b is a plot showing FBG in macaques that received only background immunosuppression.
  • FIG. 12 is a graph showing results from a competitive blockade assay using human PBMCs incubated with increasing concentrations of 2C10, 3A8, or Chi220 antibodies and stained with an APC-conjugated 2C10 to assess the ability of each antibody to cross-block 2C10.
  • FIGS. 13 a and 13 b show sequence alignment of humanized 2C10 variable regions.
  • FIG. 13 a Murine 2C10 VH sequence was aligned against human germline VH1-3 and three humanized sequences 2C10_h1, 2C10_h2, and 2C10_h3.
  • FIG. 13 b Murine 2C10 VL sequence was aligned against human germline VH3-11 and two humanized sequences 2C10_11 and 2C10_12. The 2C10 CDRs are bolded. The murine residues in humanized sequences are underlined.
  • FIG. 14 shows amino acid changes in framework 3 between 2C10HP and 2C10HB1, as well as 2C10HB2 constructs.
  • FIG. 15 shows the sequences of heavy chain and light chain variable regions for humanized 2C10 antibodies.
  • the heavy chain and light chain variable regions include 2C10HP, 2C10HB1, 2C10HB2, 2C10KP, 2C10KB1, and 2C10KB2.
  • FIG. 16 shows binding affinity of humanized 2C10 antibody to CD40 from different primate species.
  • Humanized 2C10 antibodies (h2C10) were immobilized to the surface of CM5 chip by amine coupling.
  • Different concentrations of CD40-MBP fusions of human, rhesus, and baboon were analyzed for affinity on a BIACore 3000.
  • the binding affinity was calculated with BIAevaluation software version 4.1.1.
  • FIG. 17 shows that induction of anti-KLH antibody response (IgM and IgG) was determined in monkeys immunized with KLH 3 hrs after receiving either saline, 10 or 25 mg/kg h2C10. All control animals exhibited IgG or IgM antibody responses to the KLH antigen. Individual monkeys treated with 10 mg/kg, but no animals treated with 25 mg/kg 2C10 developed either an IgG or IgM antibody responses to KLH.
  • IgM and IgG anti-KLH antibody response
  • FIG. 18 Whole blood was used for phenotyping B and T lymphocyte subsets after treatment with 25 mg/kg h2C10 (Top row) or 10 mg/kg h2C10 (Middle row), or control animals (Bottom Row). Neither dose of h2C10 had any apparent effect on the lymphocyte populations. The absence of appreciable B cell depletion was also evident in the earlier, dose-response evaluation of the primate chimeric form that included a detailed analysis of mature and immature B cell populations.
  • FIG. 19 Day 28 Humanized 2C10 fully saturated CD40 binding sites on B cells. H2C10 administered in vivo completely blocked the binding of fluorescently labeled 2C10 binding to B cells. Data illustrate results from humanized 2C10-treated and control monkeys 28 days after a single dose of 25 mg/kg (top row), 10 mg/kg (middle row) or 0 mg/kg (control; bottom row). Similar results were obtained on Days 3, 7, 14, and 21 post infusion.
  • FIG. 20 Mean serum concentrations of h2C10 for up to 28 days after treatment of monkeys with either 10 or 25 mg/kg. Concentrations of 2C10 slowly decline over time, and levels are detected over the entire duration of the study.
  • FIGS. 21 a and 21 b show the DNA and amino acid sequences of the humanized 2C10 (h2C10) in the stabilized IgG4 format.
  • FIG. 21 a shows the DNA and amino acid sequences of the heavy chain.
  • FIG. 21 b shows the DNA and amino acid sequences of the light chain.
  • SEQ ID NO: 32 DNA sequence of the heavy chain;
  • SEQ ID NO: 33 amino acid sequence of the heavy chain;
  • SEQ ID NO: 34 DNA sequence of the light chain;
  • SEQ ID NO: 35 amino acid sequence of the light chain.
  • the present disclosure relates to anti-CD40 antibodies and antibody fragments (e.g., antigen-binding portions of the antibody) that may be used in various therapeutic, prophylactic, diagnostic and other methods.
  • the antibodies can block the ability of CD40 to bind CD154 and do so without activating the cell expressing CD40 (e.g., a B cell).
  • the present antibodies or fragments thereof may be used to reduce complications associated with organ or tissue transplantation.
  • the antibodies, or antigen-binding portions thereof include, but are not limited to, humanized antibodies, human antibodies, monoclonal antibodies, chimeric antibodies, polyclonal antibodies, recombinantly expressed antibodies, as well as antigen-binding portions of the foregoing.
  • An antigen-binding portion of an antibody may include a portion of an antibody that specifically binds to CD40.
  • compositions and methods for reducing the likelihood of transplant rejection, treat transplant rejection, inducing immunosuppression, and/or treating an autoimmune disorder contain antibodies or fragments thereof that specifically bind CD40.
  • the present disclosure provides for a method of treating or ameliorating graft-versus-host disease and/or transplant rejection in a subject comprising administering to the mammal a composition comprising an antibody of the invention (or its fragment) in an amount sufficient to decrease one or more of the symptoms of graft-versus-host disease and/or transplant rejection in the subject.
  • the antibody or antigen-binding fragment is administered to a subject having an inflammatory disease or an immune disorder such as an autoimmune disease.
  • the inflammatory disease or autoimmune disease may be associated with CD40-expressing cells.
  • the invention features methods of reducing the likelihood of transplant rejection, treat transplant rejection, inducing immunosuppression, and/or treating an autoimmune disorder in a subject by administering to the subject the present antibody or antigen-binding portion thereof in an effective amount.
  • Also encompassed by the present disclosure is a method of blocking the function of CD40 in a mammal comprising administering to the mammal a composition comprising the present antibodies, or antigen-binding portions thereof, in an amount sufficient to block a CD40-mediated immune response in the mammal.
  • Another method of the disclosure relates to inhibiting the growth and/or differentiation of cells expressing CD40, comprising administering the present antibody or antigen-binding fragment to the cells, wherein the binding of the antibody or antigen-binding fragment to CD40 inhibits the growth and/or differentiation of the cells.
  • the present disclosure provides for a method of treating a subject having a CD40-associated disorder, comprising administering to the subject the present antibody or antigen-binding fragment, wherein the binding of the antibody or antigen-binding fragment to CD40 inhibits the growth and/or differentiation of cells of the CD40-associated disorder.
  • the cells may be, but are not limited to, B lymphoblastoid cells, pancreatic, lung cells, breast cells, ovarian cells, colon cells, prostate cells, skin cells, head and neck cells, bladder cells, bone cells or kidney cells.
  • the present method may be used to treat chronic lymphocytic leukemia, Burkitt's lymphoma, multiple myeloma, a T cell lymphoma, Non-Hodgkin's Lymphoma, Hodgkin's Disease, Waldenstrom's macroglobulinemia or Kaposi's sarcoma.
  • Additional methods of the present disclosure include inhibiting antibody production by B cells in a subject comprising administering to the subject an effective amount of an anti-CD40 antibody or its fragment of the present disclosure.
  • the antibody is administered in an amount effective to inhibit B cell differentiation and antibody isotype switching in the subject.
  • the antibody is administered in an amount effective to inhibit cytokine and chemokine production, and/or inhibit up-regulation of adhesion molecules in T-cells and macrophages in the subject.
  • the antibody is administered in an amount effective to inhibit activation of dendritic cells in the subject.
  • the present methods may further comprise administering a second therapeutic agent such as an immunosuppressant, a tumor necrosis factor antagonist (a TNF-antagonist), a CTLA4-antagonist, an anti-IL-6 receptor antibody, an anti-CD20 antibody, or a combination thereof.
  • a second therapeutic agent such as an immunosuppressant, a tumor necrosis factor antagonist (a TNF-antagonist), a CTLA4-antagonist, an anti-IL-6 receptor antibody, an anti-CD20 antibody, or a combination thereof.
  • the present antibodies, or antigen-binding portions thereof, may specifically bind to human CD40 and/or rhesus CD40, including recombinant and native human CD40.
  • a cell that expresses CD40 is any cell characterized by the surface expression of CD40, including, but not limited to, normal and neoplastic B cells, interdigitating cells, basal epithelial cells, carcinoma cells, macrophages, endothelial cells, follicular dendritic cells, tonsil cells, and bone marrow-derived plasma cells.
  • the humanized antibody of the present disclosure is an antibody from a non-human species where the amino acid sequences in the non-antigen binding regions (and/or the antigen-binding regions) have been altered so that the antibody more closely resembles a human antibody, and still retains its original binding ability.
  • An antibody light or heavy chain variable region consists of three hypervariable regions, referred to as complementarity determining regions (CDRs). CDRs are supported within the variable regions by framework regions (FRs).
  • the heavy chain variable region (or light chain variable region) contains three CDRs and four framework regions (FRs), arranged from amino-terminus to carboxyl-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
  • humanized antibodies are antibody molecules from non-human species having one, two, three or all CDRs from the non-human species, and one, two, three, four or all framework regions from a human immunoglobulin molecule.
  • the CDRs of the present antibodies or antigen-binding portions thereof can be from a non-human or human source.
  • the framework of the present antibodies or antigen-binding portions thereof can be human, humanized, non-human (e.g., a marine framework modified to decrease antigenicity in humans), or a synthetic framework (e.g., a consensus sequence).
  • the present antibodies, or antigen-binding portions thereof contain at least one heavy chain variable region and/or at least one light chain variable region.
  • humanized antibodies of the present disclosure can be produced by methods known in the art.
  • a humanized antibody can have one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as “import” residues, which are typically taken from an “import” variable domain.
  • Humanization can be performed following the method of Winter and co-workers (Jones et al., Nature 321:522-5, 1986; Riechmann et al., Nature 332:323-7, 1988; Verhoeyen et al., Science 239:1534-6, 1988), by substituting hypervariable region sequences for the corresponding sequences of a human antibody.
  • humanized antibodies substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species.
  • humanized antibodies are human antibodies in which at least some hypervariable region residues as well as other variable region residues are substituted by residues from analogous sites in non-human antibodies.
  • variable domains both light and heavy
  • the choice of human variable domains, both light and heavy, to be used in making the humanized antibodies may reduce antigenicity.
  • the sequence of the variable domain of a non-human (e.g., rodent such as mouse) antibody is screened against the entire library of known human variable domain sequences. The human sequence which is closest to that of the non-human is then accepted as the human framework for the humanized antibody. See, e.g., Sims et al., J. Immunol. 151:2296-308, 1993; Chothia et al., J. Mol. Biol. 196:901-17, 1987.
  • Another method uses a particular framework derived from the consensus sequence of all human antibodies of a particular subgroup of light or heavy chains.
  • the same framework may be used for several different humanized antibodies. See, e.g., Carter et al., Proc. Natl. Acad. Sci. USA 89:4285-9, 1992; Presta et al., J. Immunol. 151:2623-32, 1993.
  • Humanized antibodies can be generated by replacing sequences of the variable region that are not directly involved in antigen binding with equivalent sequences from human variable regions. Those methods include isolating, manipulating, and expressing the nucleic acid sequences that encode all or part of variable regions from at least one of a heavy or light chain. Sources of such nucleic acid are well known to those skilled in the art and, for example, may be obtained from a hybridoma producing an antibody against CD40. The recombinant DNA encoding the humanized antibody, or fragment thereof, can then be cloned into an appropriate expression vector.
  • variable regions can be sequenced, and the location of the CDRs and framework residues determined.
  • the light and heavy chain variable regions can, optionally, be ligated to corresponding constant regions.
  • CDR-grafted antibody molecules can be produced by CDR-grafting or CDR substitution. One, two, three or all CDRs of an immunoglobulin chain can be replaced.
  • all of the CDRs of a particular antibody may be from at least a portion of a non-human animal (e.g., mouse such as CDRs shown in Table 1) or only some of the CDRs may be replaced. It is only necessary to keep the CDRs required for binding of the antibody to a predetermined antigen (e.g., CD40).
  • a predetermined antigen e.g., CD40.
  • EP 519596 Jones et al., 1986, Nature, 321:552-525. Verhoeyan et al., 1988, Science, 239:1534. Beidler et al., 1988, J. Immunol., 141:4053-4060.
  • humanized antibodies are prepared by a process of analysis of the parental sequences and various conceptual humanized products using three-dimensional models of the parental and humanized sequences.
  • Three-dimensional immunoglobulin models are commonly available and are familiar to those skilled in the art.
  • Computer programs are available which illustrate and display probable three-dimensional conformational structures of selected candidate immunoglobulin sequences. Inspection of these displays permits analysis of the likely role of the residues in the functioning of the candidate immunoglobulin sequence, i.e., the analysis of residues that influence the ability of the candidate immunoglobulin to bind its antigen.
  • FR residues can be selected and combined from the recipient and import sequences so that the desired antibody characteristic, such as increased affinity for the target antigen(s), is achieved.
  • a humanized anti-CD40 antibody also includes at least a portion of an immunoglobulin constant region, typically that of a human immunoglobulin.
  • the antibody will contain both the light chain as well as at least the variable domain of a heavy chain.
  • the antibody also may include one or more of the constant domain CH1, hinge, CH2, CH3, and/or CH4 of the heavy chain, as appropriate.
  • one or more domains of the humanized antibodies will be recombinantly expressed.
  • Such recombinant expression may employ one or more control sequences, i.e., polynucleotide sequences necessary for expression of an operably linked coding sequence in a particular host organism.
  • the control sequences suitable for use in prokaryotic cells include, for example, promoter, operator, and ribosome binding site sequences.
  • Eukaryotic control sequences include, but are not limited to, promoters, polyadenylation signals, and enhancers. These control sequences can be utilized for expression and production of humanized anti-CD40 antibody in prokaryotic and eukaryotic host cells.
  • antibodies, or antigen-binding portions thereof containing one, two, or all CDRs as disclosed herein, with the other regions replaced by sequences from at least one different species including, but not limited to, human, rabbits, sheep, dogs, cats, cows, horses, goats, pigs, monkeys, apes, gorillas, chimpanzees, ducks, geese, chickens, amphibians, reptiles and other animals.
  • Human antibodies of the disclosure can be constructed by combining Fv clone variable domain sequence(s) selected from human-derived phage display libraries with known human constant domain sequences(s) (Hoogenboom et al., J. Mol. Biol. 227:381-8, 1992; Marks et al., J . Mol. Biol. 222:581-97, 1991).
  • human antibodies can be made by the hybridoma method. Human myeloma and mouse-human heteromyeloma cell lines for the production of human monoclonal antibodies have been described, for example, by Kozbor, J. Immunol. 133:3001-5, 1984; Brön et al., Monoclonal Antibody Production Techniques and Applications , pp. 51-63 (Marcel Dekker, Inc., New York, 1987); and Boerner et al., J. Immunol. 147; 86-95, 1991.
  • transgenic animals e.g., mice
  • transgenic animals e.g., mice
  • JH antibody heavy-chain joining region
  • Gene shuffling can also be used to derive human antibodies from non-human, e.g., rodent, antibodies, where the human antibody has similar affinities and specificities to the starting non-human antibody.
  • this method which is also called “epitope imprinting,” either the heavy or light chain variable region of a non-human antibody fragment obtained by phage display techniques as described herein is replaced with a repertoire of human V domain genes, creating a population of non-human chain/human chain scFv or Fab chimeras.
  • a chimeric antibody is a molecule in which different portions are derived from different animal species.
  • an antibody may contain a variable region derived from a murine antibody and a human immunoglobulin constant region.
  • Chimeric antibodies can be produced by recombinant DNA techniques. Morrison, et al., Proc Natl Acad Sci, 81:6851-6855 (1984).
  • a gene encoding a murine (or other species) monoclonal antibody molecule is digested with restriction enzymes to remove the region encoding the murine Fc, and the equivalent portion of a gene encoding a human Fc constant region is substituted.
  • Chimeric antibodies can also be created by recombinant DNA techniques where DNA encoding murine V regions can be ligated to DNA encoding the human constant regions.
  • DNA encoding murine V regions can be ligated to DNA encoding the human constant regions.
  • the heavy chain variable regions, light chain variable regions and CDRs of the murine 2C10 antibody and certain humanized anti-CD40 antibodies are shown in Table 1.
  • the antibodies or antigen-binding portions thereof include a heavy chain variable region comprising an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, about 70%, about 75%, about 80%, about 810/4 about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% identical to a heavy chain variable region amino acid sequence as set forth in any of SEQ ID NOs: 1, 19, 20, 21, 24, 25 and 26.
  • the antibodies or antigen-binding portions thereof include a light chain variable region comprising an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, about 70%/n, about 75%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% identical to a light chain variable region amino acid sequence as set forth in any of SEQ ID NOs: 12, 22, 23, 27, 28 and 29.
  • the antibodies or antigen-binding portions thereof each include both a heavy chain variable region comprising an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, about 70%, about 75%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% identical to a heavy chain variable region amino acid sequence as set forth in any of SEQ ID NOs: 11, 19, 20, 21, 24, 25 and 26, and a light chain variable region including an amino acid sequence at least about 700/a, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, about 70%, about 75%, about 80%, about
  • a heavy chain variable region of the antibodies or antigen-binding portions thereof can comprise one, two, three or more complementarity determining regions (CDRs) that are at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, about 70%, about 75%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% identical to the CDRs of a heavy chain variable region of the 2C10 antibody (CDR1, CDR2 and CDR3 as set forth in SEQ ID NOs: 13, 14, 15, respectively).
  • CDRs complementarity determining regions
  • a light chain variable region of the antibodies or antigen-binding portions thereof can comprise one, two, three or more CDRs that are at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, about 70%, about 75%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% identical to the CDRs of a light chain variable region of the 2C10 antibody (CDR1, CDR2 and CDR3 as set forth in SEQ ID NOs: 16, 17, 18, respectively).
  • a heavy chain variable region of the present antibodies, or antigen-binding portions thereof can comprise one, two, three or more complementarity determining regions (CDRs) that are at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, about 70%, about 75%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% identical to the CDRs of a heavy chain variable region of the 2C10 antibody (CDR1, CDR2 and CDR3 as set forth in SEQ ID NOs: 13, 14, 15, respectively), and a light chain variable region of the antibodies or antigen-binding portions thereof can comprise one, two, three or more CDRs that are at least about 70%, at least about 7
  • a heavy chain variable region of the antibodies or antigen-binding portions thereof can include three CDRs that are at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, about 70%, about 75%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% identical to the CDRs of a heavy chain variable region of the 2C10 antibody (CDR1, CDR2 and CDR3 as set forth in SEQ ID NOs: 13, 14, 15, respectively).
  • a light chain variable region of the antibodies or antigen-binding portions thereof includes three CDRs that are at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, about 70%, about 75%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%/a, about 99% or about 100% identical to the CDRs of a light chain variable region of the 2C10 antibody (CDR1, CDR2 and CDR3 as set forth in SEQ ID NOs: 16, 17, 18, respectively).
  • a heavy chain variable region of the antibodies or antigen-binding portions thereof includes three CDRs that are at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, about 70%, about 75%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% identical to the CDRs of a heavy chain variable region of the 2C10 antibody (CDR1, CDR2 and CDR3 as set forth in SEQ ID NOs: 13, 14, 15, respectively), and a light chain variable region of the antibodies or antigen-binding portions thereof includes three CDRs that are at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about
  • a heavy chain variable region of the antibodies or antigen-binding portions thereof includes three CDRs that are identical to CDRs of a heavy chain variable region of the 2C10 antibody (CDR1, CDR2 and CDR3 as set forth in SEQ ID NOs: 13, 14, 15, respectively), and a light chain variable region of the antibodies or antigen-binding portions thereof includes three CDRs that are identical to CDRs of a light chain variable region of the 2C10 antibody (CDR1, CDR2 and CDR3 as set forth in SEQ ID NOs: 16, 17, 18, respectively).
  • antibodies with a heavy chain variable region and a light chain variable region having amino acid sequences at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, about 70%, about 75%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%, identical to the heavy chain variable region (SEQ ID NO: 11) and light chain variable region (SEQ ID NO: 12) of the antibody 2C10, respectively.
  • anti-CD40 antibodies or antigen-binding portions thereof include, for example, the CDRs of heavy chain variable regions and/or light chain variable regions of 2C10.
  • the antibody or antigen-binding portion thereof contains a heavy chain variable region and a light chain variable region identical to a heavy chain variable region and light chain variable region of the 2C10 antibody (SEQ ID NO: 11 and SEQ ID NO: 12, respectively).
  • the antibodies or antigen-binding portions thereof specifically bind to an epitope that overlaps with, or are at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, about 70%, about 75%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100%, identical to an epitope bound by the 2C10 antibody.
  • the epitope may be present within the sequence of SEQ ID NO: 6, or may be present within the sequence of amino acids 8-40 of SEQ ID NO: 6.
  • CDRs corresponding to the CDRs in Table 1 have sequence variations.
  • CDRs, in which 1, 2 3, 4, 5, 6, 7 or 8 residues, or less than 20%, less than 30%, or less than about 40%, of total residues in the CDR, are substituted or deleted can be present in an antibody (or antigen-binding portion thereof) that binds CD40.
  • antibodies or antigen-binding portions thereof in which specific amino acids have been substituted, deleted or added. These alternations do not have a substantial effect on the peptide's biological properties such as binding activity.
  • antibodies may have amino acid substitutions in the framework region, such as to improve binding to the antigen.
  • a selected, small number of acceptor framework residues can be replaced by the corresponding donor amino acids.
  • the donor framework can be a mature or germline human antibody framework sequence or a consensus sequence.
  • Guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie et al., Science, 247: 1306-1310 (1990). Cunningham et al., Science, 244: 1081-1085 (1989).
  • the present peptides may be the functionally active variant of antibodies of antigen-binding portions thereof disclosed herein, e.g., with less than about 30%, about 25%, about 20%, about 15%, about 10%, about 5% or about 1% amino acid residues substituted or deleted but retain essentially the same immunological properties including, but not limited to, binding to CD40.
  • the antibodies or antigen-binding portions thereof may also include variants, analogs, orthologs, homologs and derivatives of peptides, that exhibit a biological activity, e.g., binding of an antigen such as CD40.
  • the peptides may contain one or more analogs of an amino acid (including, for example, non-naturally occurring amino acids, amino acids which only occur naturally in an unrelated biological system, modified amino acids from mammalian systems etc.), peptides with substituted linkages, as well as other modifications known in the art.
  • the antibody, or antigen-binding portion thereof can be derivatized or linked to another functional molecule.
  • an antibody can be functionally linked (by chemical coupling, genetic fusion, noncovalent interaction, etc.) to one or more other molecular entities, such as another antibody, a detectable agent, an immunosuppressant, a cytotoxic agent, a pharmaceutical agent, a protein or peptide that can mediate association with another molecule (such as a streptavidin core region or a polyhistidine tag), amino acid linkers, signal sequences, immunogenic carriers, or ligands useful in protein purification, such as glutathione-S-transferase, histidine tag, and staphylococcal protein A.
  • Cytotoxic agents may include radioactive isotopes, chemotherapeutic agents, and toxins such as enzymatically active toxins of bacterial, fungal, plant, or animal origin, and fragments thereof. Such cytotoxic agents can be coupled to the humanized antibodies of the present disclosure using standard procedures, and used, for example, to treat a patient indicated for therapy with the antibody.
  • One type of derivatized protein is produced by crosslinking two or more proteins (of the same type or of different types).
  • Suitable crosslinkers include those that are heterobifunctional, having two distinct reactive groups separated by an appropriate spacer (e.g., m-maleimidobenzoyl-N-hydroxysuccinimide ester) or homobifunctional (e.g., disuccinimidyl suberate).
  • Useful detectable agents with which a protein can be derivatized (or labeled) include fluorescent agents, various enzymes, prosthetic groups, luminescent materials, bioluminescent materials, and radioactive materials.
  • Non-limiting, exemplary fluorescent detectable agents include fluorescein, fluorescein isothiocyanate, rhodamine, and, phycoerythrin.
  • a protein or antibody can also be derivatized with detectable enzymes, such as alkaline phosphatase, horseradish peroxidase, beta-galactosidase, acetylcholinesterase, glucose oxidase and the like.
  • a protein can also be derivatized with a prosthetic group (e.g., streptavidin/biotin and avidin/biotin).
  • the humanized anti-CD40 antibody or its fragment is used unlabeled and detected with a labeled antibody that binds the humanized anti-CD40 antibody or its fragment.
  • the antibodies can be full-length or can include a fragment (or fragments) of the antibody having an antigen-binding portion, including, but not limited to, Fab, F(ab′)2, Fab′, F(ab)′, Fv, single chain Fv (scFv), bivalent scFv (bi-scFv), trivalent scFv (tri-scFv), Fd, dAb fragment (e.g., Ward et al., Nature, 341:544-546 (1989)), an isolated CDR, diabodies, triabodies, tetrabodies, linear antibodies, single-chain antibody molecules, and multispecific antibodies formed from antibody fragments.
  • Single chain antibodies produced by joining antibody fragments using recombinant methods, or a synthetic linker are also encompassed by The present disclosure.
  • Papain digestion of antibodies produces two identical antigen-binding fragments, called “Fab” fragments, each with a single antigen-binding site, and a residual “Fc” fragment, whose name reflects its ability to crystallize readily. Pepsin treatment yields an F(ab′) 2 fragment that has two antigen-combining sites and is still capable of cross-linking antigen.
  • Fv is the minimum antibody fragment which contains a complete antigen-binding site.
  • a two-chain Fv species consists of a dimer of one heavy- and one light-chain variable domain in tight, non-covalent association.
  • scFv single-chain Fv
  • one heavy- and one light-chain variable domain can be covalently linked by a flexible peptide linker such that the light and heavy chains can associate in a “dimeric” structure analogous to that in a two-chain Fv species. It is in this configuration that the three CDRs of each variable domain interact to define an antigen-binding site on the surface of the V H -V L dimer.
  • the six CDRs confer antigen-binding specificity to the antibody.
  • the Fab fragment contains the heavy- and light-chain variable domains and also contains the constant domain of the light chain and the first constant domain (CH1) of the heavy chain.
  • Fab′ fragments differ from Fab fragments by the addition of a few residues at the carboxyl terminus of the heavy chain CH1 domain including one or more cysteines from the antibody hinge region.
  • Fab′-SH is the designation for Fab′ in which the cysteine residue(s) of the constant domains bear a free thiol group.
  • F(ab′) 2 antibody fragments originally were produced as pairs of Fab′ fragments which have hinge cysteines between them. Other chemical couplings of antibody fragments are also known.
  • Single-chain Fv or scFv antibody fragments comprise the V H and V L domains of antibody, where these domains are present in a single polypeptide chain.
  • the scFv polypeptide further comprises a polypeptide linker between the V H and V L domains which enables the scFv to form the desired structure for antigen binding.
  • Diabodies are antibody fragments with two antigen-binding sites, which fragments comprise a heavy-chain variable domain (V H ) connected to a light-chain variable domain (V L ) in the same polypeptide chain (V H -V L ). By using a linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with the complementary domains of another chain and create two antigen-binding sites.
  • Diabodies may be bivalent or bispecific. Diabodies are described more fully in, for example, European Patent No. 404,097, PCT Publication WO 1993/01161; Hudson et al., Nat. Med. 9:129-34, 2003; and Hollinger et al., Proc. Natl. Acad. Sci. USA 90:6444-8, 1993. Triabodies and tetrabodies are also described in Hudson et al., Nat. Med. 9:129-34, 2003.
  • Antibody fragments may be generated by traditional means, such as enzymatic digestion, or by recombinant techniques. In certain circumstances there are advantages of using antibody fragments, rather than whole antibodies. The smaller size of the fragments allows for rapid clearance, and may lead to improved access to solid tumors. For a review of certain antibody fragments, see Hudson et al. Nat. Med. 9:129-134, 2003.
  • F(ab′)2 fragments are isolated directly from recombinant host cell culture.
  • Fab and F(ab′) 2 fragment with increased in vivo half-life comprising salvage receptor binding epitope residues are described in U.S. Pat. No. 5,869,046. Other techniques for the production of antibody fragments will be apparent to the skilled practitioner.
  • the present antibody or antigen-binding portion thereof may comprise at least one constant domain, such as, (a) an IgG constant domain; (b) an IgA constant domain, etc.
  • All antibody isotypes are encompassed by the present disclosure, including IgG (e.g., IgG1, IgG2, IgG3, IgG4), IgM, IgA (IgA1, IgA2), IgD or IgE.
  • the antibodies or antigen-binding portions thereof may be mammalian (e.g., mouse, human) antibodies or antigen-binding portions thereof.
  • the light chains of the antibody may be of kappa or lambda type.
  • An alternative humanized anti-CD40 antibody can comprise sequences from more than one immunoglobulin class or isotype, and selecting particular constant domains to optimize desired effector functions is within the ordinary skill in the art.
  • the antibodies or antigen-binding portions thereof of The present disclosure may be monospecific, bi-specific or multi-specific. Multi-specific or bi-specific antibodies or fragments thereof may be specific for different epitopes of one target polypeptide (e.g., CD40) or may contain antigen-binding domains specific for more than one target polypeptide (e.g., antigen-binding domains specific for CD40 and other antigen relating to transplant rejection or autoimmune disease).
  • a multispecific antibody or antigen-binding portion thereof comprises at least two different variable domains, wherein each variable domain is capable of specifically binding to a separate antigen or to a different epitope on the same antigen. Tutt et al., 1991, J. Immunol.
  • the present antibodies can be linked to or co-expressed with another functional molecule, e.g., another peptide or protein.
  • another functional molecule e.g., another peptide or protein.
  • an antibody or fragment thereof can be functionally linked (e.g., by chemical coupling, genetic fusion, noncovalent association or otherwise) to one or more other molecular entities, such as another antibody or antibody fragment to produce a bi-specific or a multispecific antibody with a second binding specificity.
  • the present disclosure includes bi-specific antibodies wherein one arm of an immunoglobulin is specific for CD40, and the other arm of the immunoglobulin is specific for a second therapeutic target or is conjugated to a therapeutic moiety such as an immunosuppressant.
  • the present disclosure provides for methods for making an antibody or antigen-binding portion thereof that specifically binds to CD40.
  • a non-human animal is immunized with a composition that includes CD40, and then a specific antibody is isolated from the animal.
  • the method can further include evaluating binding of the antibody to CD40.
  • the present disclosure provides for a method for making a hybridoma that expresses an antibody that specifically binds to CD40.
  • the method contains the following steps: immunizing an animal with a composition that includes CD40 or its fragment; isolating splenocytes from the animal; generating hybridomas from the splenocytes; and selecting a hybridoma that produces an antibody that specifically binds to CD40.
  • CD40 is used to immunize mice intraperitoneally or intravenously.
  • One or more boosts may or may not be given.
  • the titers of the antibodies in the plasma can be monitored by, e.g., ELISA (enzyme-linked immunosorbant assay) or flow cytometry.
  • Mice with sufficient titers of anti-CD40 antibodies are used for fusions. Mice may or may not be boosted with antigen 3 days before sacrifice and removal of the spleen.
  • the mouse splenocytes are isolated and fused with PEG to a mouse myeloma cell line.
  • the resulting hybridomas are then screened for the production of antigen-specific antibodies. Cells are plated, and then incubated in selective medium.
  • Adjuvants that may be used to increase the immunogenicity of CD40 include any agent or agents that act to increase an immune response to peptides or combination of peptides.
  • adjuvants include alum, aluminum phosphate, aluminum hydroxide, MF59 (4.3% w/v squalene, 0.5% w/v polysorbate 80 (Tween 80), 0.5% w/v sorbitan trioleate (Span 85)), CpG-containing nucleic acid, QS21 (saponin adjuvant), MPL (Monophosphoryl Lipid A), 3DMPL (3-O-deacylated MPL), extracts from Aquilla, ISCOMS (see, e.g., Sjolander et al.
  • the immunized animal can be any animal that is capable of producing recoverable antibodies when administered an immunogen, such as, but not limited to, rabbits, mice, rats, hamsters, goats, horses, monkeys, baboons and humans.
  • the host is transgenic and produces human antibodies, e.g., a mouse expressing the human immunoglobulin gene segments.
  • U.S. Pat. Nos. 8,236,311; 7,625,559 and 5,770,429 the disclosure of each of which is incorporated herein by reference in its entirety.
  • Lonberg, N. and Huszar D., Intern. Rev. Immunol., 13: 65-93, 1995. Harding, F. and Lonberg, N., Ann. N.Y. Acad. Sci., 764:536-546, 1995.
  • the present antibodies or portions thereof can be produced by host cells transformed with DNA encoding light and heavy chains (or portions thereof) of a desired antibody.
  • Antibodies (or portions thereof) can be isolated and purified from these culture supernatants and/or cells using standard techniques.
  • a host cell may be transformed with DNA encoding the light chain, the heavy chain, or both, of an antibody.
  • Recombinant DNA technology may also be used to remove some or all of the DNA encoding at least a portion of either or both of the light and heavy chains that is not necessary for binding, e.g., the constant region.
  • the invention also encompasses a nucleic acid or polynucleotide encoding at least one of the present antibody or antigen-binding portion thereof that specifically binds to CD40.
  • the nucleic acid may be expressed in a cell to produce the present antibody or antigen-binding portion thereof.
  • the isolated nucleic acid or polynucleotide of the present disclosure comprises at least one sequence encoding a peptide at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, about 70%, about 75%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% identical to any of SEQ ID NOs: 11-29.
  • the invention also features expression vectors including at least one nucleic acid or polynucleotide encoding a peptide at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, about 70%, about 75%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% identical to any of SEQ ID NOs: 11-29.
  • Nucleic acid molecules encoding a functionally active variant of the present antibody or antigen-binding portion thereof are also encompassed by the present disclosure. These nucleic acid molecules may hybridize with a nucleic acid encoding any of the present antibody or antigen-binding portion thereof under medium stringency, high stringency, or very high stringency conditions. Guidance for performing hybridization reactions can be found in Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. 6.3.1-6.3.6, 1989, which is incorporated herein by reference.
  • Specific hybridization conditions referred to herein are as follows: (1) medium stringency hybridization conditions: 6 ⁇ SSC at about 45° C., followed by one or more washes in 0.2 ⁇ SSC, 0.1% SDS at 60° C.; (2) high stringency hybridization conditions: 6 ⁇ SSC at about 45C, followed by one or more washes in 0.2 ⁇ SSC, 0.1% SDS at 65° C.; and (3) very high stringency hybridization conditions: 0.5 M sodium phosphate, 7% SDS at 65° C., followed by one or more washes at 0.2 ⁇ SSC, 1% SDS at 65° C.
  • a nucleic acid or polynucleotide encoding the present antibody or antigen-binding portion thereof may be introduced into an expression vector that can be expressed in a suitable expression system, followed by isolation or purification of the expressed antibody or antigen-binding portion thereof.
  • a nucleic acid encoding the present antibody or antigen-binding portion thereof can be translated in a cell-free translation system.
  • the present nucleic acids can be expressed in various suitable cells, including prokaryotic and eukaryotic cells, e.g., bacterial cells, (e.g., E. coli ), yeast cells, plant cells, insect cells, and mammalian cells.
  • prokaryotic and eukaryotic cells e.g., bacterial cells, (e.g., E. coli ), yeast cells, plant cells, insect cells, and mammalian cells.
  • bacterial cells e.g., E. coli
  • yeast cells e.g., plant cells, insect cells, and mammalian cells.
  • a number of mammalian cell lines are known in the art and include immortalized cell lines available from the American Type Culture Collection (ATCC).
  • ATCC American Type Culture Collection
  • Non-limiting examples of the cells include all cell lines of mammalian origin or mammalian-like characteristics, including but not limited to, parental cells, derivatives and/or engineered variants of monkey kidney cells (COS, e.g., COS-1, COS-7), HEK293, baby hamster kidney (BHK, e.g., BHK21), Chinese hamster ovary (CHO), NS0, PerC6, BSC-1, human hepatocellular carcinoma cells (e.g., Hep G2), SP2/0, HeLa, Madin-Darby bovine kidney (MDBK), myeloma and lymphoma cells.
  • the engineered variants include, e.g., glycan profile modified and/or site-specific integration site derivatives.
  • the present disclosure also provides for cells comprising the nucleic acids described herein.
  • the cells may be a hybridoma or transfectant.
  • the present antibody or antigen-binding portion thereof can be expressed in various cells. The types of the cells are discussed herein.
  • the antibody or its portion can be produced intracellularly, in the periplasmic space, or directly secreted into the medium. If the antibody is produced intracellularly, the cells may be disrupted to release protein as a first step. Particulate debris, either host cells or lysed fragments, can be removed, for example, by centrifugation or ultrafiltration. Carter et al., 1992, Bio/Technology 10:163-167 describes a procedure for isolating antibodies that are secreted to the periplasmic space of E. coli .
  • cell paste is thawed in the presence of sodium acetate (pH 3.5), EDTA, and phenylmethylsulfonylfluoride (PMSF) over about 30 minutes.
  • PMSF phenylmethylsulfonylfluoride
  • Cell debris can be removed by centrifugation.
  • supernatants from such expression systems may be first concentrated using a commercially available protein concentration filter, for example, an Amicon or Millipore Pellicon ultrafiltration unit.
  • a commercially available protein concentration filter for example, an Amicon or Millipore Pellicon ultrafiltration unit.
  • a variety of methods can be used to isolate the antibody from the host cell.
  • the antibody or its portion prepared from the cells can be purified using, for example, hydroxylapatite chromatography, gel electrophoresis, dialysis, and affinity chromatography, with affinity chromatography being a typical purification technique.
  • affinity chromatography is a typical purification technique.
  • the suitability of protein A as an affinity ligand depends on the species and isotype of any immunoglobulin Fc domain that is present in the antibody.
  • Protein A can be used to purify antibodies that are based on human gamma1, gamma2, or gamma4 heavy chains (see, e.g., Lindmark et al., 1983 J. Immunol. Meth. 62:1-13).
  • Protein G is recommended for all mouse isotypes and for human gamma3 (see, e.g., Guss et al., 1986 EMBO J. 5:1567-1575).
  • a matrix to which an affinity ligand is attached is most often agarose, but other matrices are available. Mechanically stable matrices such as controlled pore glass or poly(styrenedivinyl)benzene allow for faster flow rates and shorter processing times than can be achieved with agarose.
  • the antibody comprises a C.sub.H3 domain
  • the Bakerbond ABXTM resin J. T. Baker, Phillipsburg, N.J.
  • the mixture comprising the antibody of interest and contaminants may be subjected to low pH hydrophobic interaction chromatography using an elution buffer at a pH between about 2.5-4.5, typically performed at low salt concentrations (e.g., from about 0-0.25M salt).
  • Hybridomas or other cells that produce antibodies that bind, preferably with high affinity, to CD40 can then be subcloned and further characterized.
  • One clone from each hybridoma or cell, which retains the reactivity of the parent cells (by ELISA), can then be chosen for making a cell bank, and for antibody purification.
  • the present antibody or antigen-binding portion thereof can be synthesized by solid phase procedures well known in the art.
  • Solid Phase Peptide Synthesis A Practical Approach by E. Atherton and R. C. Sheppard, published by IRL at Oxford University Press (1989). Methods in Molecular Biology, Vol. 35: Peptide Synthesis Protocols (ed. M. W. Pennington and B. M. Dunn), chapter 7. Solid Phase Peptide Synthesis, 2nd Ed., Pierce Chemical Co., Rockford, Ill. (1984).
  • G. Barany and R. B. Merrifield The Peptides: Analysis, Synthesis, Biology, editors E. Gross and J. Meienhofer, Vol. 1 and Vol. 2, Academic Press, New York, (1980), pp. 3-254. M. Bodansky, Principles of Peptide Synthesis, Springer-Verlag, Berlin (1984).
  • Additional antibodies against the CD40 epitope recognized by 2C10 can be made, e.g., using a suitable method for making antibodies.
  • a coding sequence for an epitope recognized by the 2C10 antibody is expressed as a C-terminal fusion with glutathione S-transferase (GST) (Smith et al., Gene 67:31-40, 1988).
  • GST glutathione S-transferase
  • the fusion protein is purified on glutathione-Sepharose beads, eluted with glutathione, cleaved with thrombin (at an engineered cleavage site), and purified for immunization of rabbits.
  • peptides corresponding to relatively unique immunogenic regions of a polypeptide of the invention can be generated and coupled to keyhole limpet hemocyanin (KLH) through an introduced C-terminal lysine.
  • KLH keyhole limpet hemocyanin
  • Antiserum to each of these peptides is similarly affinity purified on peptides conjugated to BSA, and specificity is tested by ELISA or Western blot analysis using peptide conjugates, or by Western blot or immunoprecipitation using the polypeptide expressed as a GST fusion protein.
  • monoclonal antibodies that specifically bind the CD40 epitope recognized by the 2C10 antibody can be prepared using standard hybridoma technology (see, e.g., Kohler et al., Nature 256:495-7, 1975; Kohler et al., Eur. J. Immunol. 6:511-9, 1976; Kohler et al., Eur. J. Immunol. 6:292-5, 1976; Hammerling et al., Monoclonal Antibodies and T Cell Hybridomas , Elsevier, N Y, 1981). Once produced, monoclonal antibodies can also be tested for specific recognition by Western blot or immunoprecipitation analysis. Alternatively, monoclonal antibodies can be prepared using the polypeptide of the invention described above and a phage display library (Vaughan et al., Nat. Biotechnol. 14:309-14, 1996).
  • Epitopic fragments can be generated by standard techniques, e.g., using PCR and cloning the fragment into a pGEX expression vector. Fusion proteins are expressed in E. coli and purified using a glutathione agarose affinity matrix. To minimize potential problems of low affinity or specificity of antisera, two or three such fusions are generated for each protein, and each fusion is injected into at least two rabbits. Antisera are raised by injections in a series, and can include, for example, at least three booster injections.
  • Polyclonal antibodies can be isolated from the milk or colostrum of, e.g., immunized cows. Bovine colostrum contains 28 g of IgG per liter, while bovine milk contains 1.5 g of IgG per liter (Ontsouka et al, J. Dairy Sci. 86:2005-11, 2003). Polyclonal antibodies can also be isolated from the yolk of eggs from immunized chickens (Sarker et al., J. Pediatr. Garoenterol. Nutr. 32:19-25, 2001).
  • Anti-CD40 antibodies can be characterized for binding to CD40 by a variety of known techniques. For example, in an ELISA, microtiter plates are coated with CD40 or a fragment of CD40 in PBS, and then blocked with irrelevant proteins such as bovine serum albumin (BSA) diluted in PBS. Dilutions of plasma from CD40-immunized mice (or solutions containing anti-CD40 antibodies) are added to each well and incubated.
  • BSA bovine serum albumin
  • the plates are washed and then incubated with a secondary antibody conjugated to an enzyme (e.g., alkaline phosphatase). After washing, the plates are developed with the enzyme's substrate (e.g., ABTS), and analyzed at a specific OD.
  • an enzyme e.g., alkaline phosphatase
  • the plates are developed with the enzyme's substrate (e.g., ABTS), and analyzed at a specific OD.
  • the antibody can be biotinylated which can then be detected with a streptavidin labeled probe.
  • Anti-CD40 antibodies can be tested for reactivity with CD40 by Western blotting.
  • Antibodies, or antigen-binding fragments, variants or derivatives thereof of the present disclosure can also be described or specified in terms of their binding affinity to an antigen.
  • the affinity of an antibody for an antigen can be determined experimentally using any suitable method (see, e.g., Berzofsky et al., “Antibody-Antigen Interactions,” In Fundamental Immunology, Paul, W. E., Ed., Raven Press; New York, N.Y. (1984); Kuby, Janis Immunology, W. H. Freeman and Company: New York, N.Y. (1992); and methods described herein).
  • the measured affinity of a particular antibody-antigen interaction can vary if measured under different conditions (e.g., salt concentration, pH).
  • affinity and other antigen-binding parameters e.g., K D , K a , K d
  • K D , K a , K d are preferably made with standardized solutions of antibody and antigen, and a standardized buffer.
  • the present antibodies or antigen-binding portions thereof specifically bind to CD40 with a dissociation constant (K D ) of less than about 10 ⁇ 7 M, less than about 10 ⁇ 8 M, less than about 10 ⁇ 9 M, less than about 10 ⁇ 10 M, less than about 10 ⁇ 11 M, less than about 10 ⁇ 12 M, from about 10 ⁇ 7 M to about 10 ⁇ 12 M, from about 10 ⁇ 8 M to about 10 ⁇ 11 M, from about 10 ⁇ 9 M to about 10 ⁇ 10 M, or from about 10 ⁇ 8 M to about 10 ⁇ 12 M.
  • K D dissociation constant
  • Assays may also be used to test the ability of an antibody (or its fragment) to block CD40 binding to CD154, or inhibit or decrease CD40-mediated responses.
  • inhibits binding and “blocks binding” (e.g., inhibition/blocking of binding of CD154 to CD40) are used interchangeably and encompass both partial and complete inhibition/blocking. Inhibition and blocking are also intended to include any measurable decrease in the binding of CD154 to CD40 when in contact with an anti-CD40 antibody or portions thereof as disclosed herein as compared to ligand not in contact with an anti-CD40 antibody, e.g., the blocking of CD154 to CD40 by at least about 10%, 20%, 30%, 40%, 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100/o.
  • activation of B cells, or inhibition thereof may be determined by measuring expression of one or more markers selected from CD23, CD80, CD86, and any additional suitable marker on CD20+ cells.
  • the present antibodies or fragments thereof may be characterized by their effects on T cell-mediated antibody responses.
  • the antibodies or fragments thereof may inhibit IgM and/or IgG production in a mammal, when the antibody, or an antigen-binding portion thereof, is administered to the mammal at a dosage ranging from about 1 mg/kg body weight to about 50 mg/kg body weight, from about 2 mg/kg body weight to about 40 mg/kg body weight, from about 3 mg/kg body weight to about 30 mg/kg body weight, from about 5 mg/kg body weight to about 20 mg/kg body weight, from about 8 mg/kg body weight to about 13 mg/kg body weight, about 1 mg/kg body weight, about 2 mg/kg body weight, about 5 mg/kg body weight, about 10 mg/kg body weight, about 15 mg/kg body weight, about 20 mg/kg body weight, about 25 mg/kg body weight, about 30 mg/kg body weight, about 35 mg/kg body weight, about 40 mg/kg body weight, about 50 mg/kg body weight, about 60 mg/kg
  • the present antibodies or fragments thereof may be characterized by their effects on prolonging graft survival post transplantation.
  • the present antibodies or fragments thereof, alone or in combination with one or more other immunosuppressants, may prolong graft survival by about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 2 fold, about 5 fold, about 10 fold, about 15 fold, about 20 fold, about 25 fold, about 30 fold, about 35 fold, about 40 fold, about 45 fold, about 50 fold, about 55 fold, greater than about 40%, greater than about 50%, greater than about 60%, greater than about 70%, greater than about 80%, or greater than about 90%, greater than about 2 fold, greater than about 5 fold, greater than about 10 fold, greater than about 20 fold, greater than about 30 fold, or greater than about 40 fold.
  • the present antibodies or fragments thereof may prolong islet allograft survival.
  • the present antibody, or antigen-binding fragment thereof a) may block binding of CD40 to CD154; c) may block activation of antigen presenting cells (e.g., B cells, dendritic cells, macrophages, etc.); d) may or may not induce depletion of B cells; e) may or may not inhibit or decrease cytokine release from antigen presenting cells; f) may or may not induce tumor cell apoptosis; g) may or may not inhibit tumor cell proliferation; h) may or may not kills tumor cell; i) may or may not stimulate anti-tumor T cell responses; and/or j) may or may not reduce established tumors.
  • antigen presenting cells e.g., B cells, dendritic cells, macrophages, etc.
  • d) may or may not induce depletion of B cells
  • e) may or may not inhibit or decrease cytokine release from antigen presenting cells
  • f) may or may not induce tumor cell apop
  • the antibodies described herein may have or induce a combination of any one or more of these attributes or activities. Tai, et al., Cancer Res. 2005, 1; 65(13):5898-906; Luqman et al., Blood 112:711-720, 2008.
  • the antibodies or portions thereof described herein may also be tested for effects on CD40 internalization, in vitro and in vivo efficacy, etc.
  • Such assays may be performed using well-established protocols known to the skilled person (see e.g., Current Protocols in Molecular Biology (Greene Publ. Assoc. Inc. & John Wiley & Sons, Inc., NY, N.Y.); Current Protocols in Immunology (Edited by: John E. Coligan, Ada M. Kruisbeek, David H. Margulies, Ethan M. Shevach, Warren Strober 2001 John Wiley & Sons, NY, N.Y.); or commercially available kits.
  • the present antibodies or antigen-binding portions thereof have in vitro and in vivo therapeutic, prophylactic, and/or diagnostic utilities.
  • cells can be cultured in vitro in culture medium and contacted by the anti-CD40 antibody or fragment thereof.
  • the antibodies or antigen-binding portions thereof can be administered in a subject, as part of an in vivo (e.g., therapeutic or prophylactic) protocol.
  • the contacting step is effected in a subject and includes administering an anti-CD40 antibody or portion thereof to the subject under conditions effective to permit binding of the antibody, or portion thereof, to CD40 in the subject.
  • the antibodies or antigen-binding portions thereof can be administered to reduce the likelihood of, or increase the duration prior to, transplant rejection, inducing immunosuppression, or treating an autoimmune disorder.
  • the antibodies or antibody fragments described herein may be used in any situation in which immunosuppression is desired (e.g., transplant rejection or autoimmune disorders). These antibodies are particularly useful for treating transplant rejection, e.g., reducing the likelihood that a particular transplant is rejected by the host or increasing the time before rejection takes place.
  • the antibodies or antibody fragments described herein can be used in conjunction with transplantation of any organ or any tissue that is suitable for transplantation.
  • Non-limiting exemplary organs include heart, kidney, lung, liver, pancreas, intestine, and thymus; non-limiting exemplary tissues include bone, tendon, cornea, skin, heart valve, vein, and bone marrow.
  • the antibodies and antibody fragments can also be used to treat autoimmune disorders.
  • the autoimmune disorder may be associated with or caused by the presence of an autoantibody.
  • Autoimmune diseases that may be treated with the present antibodies or fragments thereof include, but are not limited to, systemic lupus erythematosus (SLE), CREST syndrome (calcinosis, Raynaud's syndrome, esophageal dysmotility, sclerodactyl, and telangiectasia), opsoclonus, inflammatory myopathy (e.g., polymyositis, dermatomyositis, and inclusion-body myositis), systemic scleroderma, primary biliary cirrhosis, celiac disease (e.g., gluten sensitive enteropathy), dermatitis herpetiformis, Miller-Fisher Syndrome, acute motor axonal neuropathy (AMAN), multifocal motor neuropathy with conduction block, autoimmune hepatitis, antiphospholipid syndrome, Wegener's granulomatosis, mic
  • autoimmune disorders include pernicious anemia, Addison's disease, psoriasis, inflammatory bowel disease, psoriatic arthritis, Sjögren's syndrome, lupus erythematosus (e.g., discoid lupus erythematosus, drug-induced lupus erythematosus, and neonatal lupus erythematosus), multiple sclerosis, and reactive arthritis.
  • pernicious anemia Addison's disease, psoriasis, inflammatory bowel disease, psoriatic arthritis, Sjögren's syndrome, lupus erythematosus (e.g., discoid lupus erythematosus, drug-induced lupus erythematosus, and neonatal lupus erythematosus), multiple sclerosis, and reactive arthritis.
  • Additional disorders include, for example, polymyositis, dermatomyositis, multiple endocrine failure, Schmidt's syndrome, autoimmune uveitis, adrenalitis, thyroiditis, autoimmune thyroid disease, gastric atrophy, chronic hepatitis, lupoid hepatitis, atherosclerosis, presenile dementia, demyelinating diseases, subacute cutaneous lupus erythematosus, hypoparathyroidism, Dressler's syndrome, autoimmune thrombocytopenia, idiopathic thrombocytopenic purpura, hemolytic anemia, pemphigus vulgaris, pemphigus, alopecia arcata, pemphigoid, scleroderma, progressive systemic sclerosis, adult onset diabetes mellitus (e.g., type II diabetes), male and female autoimmune infertility, ankylosing spondolytis, ulcerative colitis,
  • the present antibody or its fragment can be used in the treatment of various disorders associated with the expression of CD40.
  • a disorder may be any condition that would benefit from treatment with the present antibody or its fragment. This includes chronic and acute disorders or diseases including those pathological conditions that predispose the mammal to the disorder in question.
  • disorders to be treated herein include autoimmune diseases, immunologic disorders, inflammatory disorders, cancer, hematological malignancies, benign and malignant tumors, leukemias, lymphoid malignancies, and angiogenic disorders.
  • CD40-associated disorder or “CD40-associated disease” refers to a condition in which modification or elimination of cells expressing CD40 is indicated. These include CD40-expressing cells demonstrating abnormal proliferation or CD40-expressing cells that are associated with cancerous or malignant growth. CD40-associated disorders include, but are not limited to, diseases and disorders of the immune system, such as autoimmune disorders and inflammatory disorders.
  • Such conditions include, but are not limited to, rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), scleroderma, Sjogren's syndrome, multiple sclerosis, psoriasis, inflammatory bowel disease (e.g., ulcerative colitis and Crohn's disease), pulmonary inflammation, asthma, and idiopathic thrombocytopenic purara (ITP).
  • RA rheumatoid arthritis
  • SLE systemic lupus erythematosus
  • Sjogren's syndrome multiple sclerosis
  • psoriasis e.g., inflammatory bowel disease (e.g., ulcerative colitis and Crohn's disease)
  • pulmonary inflammation e.g., asthma, and idiopathic thrombocytopenic purara (ITP).
  • Such disorders also include, but are not limited to, leukemias, lymphomas, including B cell lymphoma and non-Hodgkin's lymphoma, multiple myeloma, Waldenstrom's macroglobulinemia; solid tumors, including sarcomas, such as osteosarcoma, Ewing's sarcoma, malignant melanoma, adenocarcinoma, including ovarian adenocarcinoma, Kaposi's sarcoma/Kaposi's tumor and squamous cell carcinoma.
  • leukemias lymphomas, including B cell lymphoma and non-Hodgkin's lymphoma, multiple myeloma, Waldenstrom's macroglobulinemia
  • solid tumors including sarcomas, such as osteosarcoma, Ewing's sarcoma, malignant melanoma, adenocarcinoma, including ovarian adenocarcinoma
  • CD40-expressing cancers that can be treated or prevented by the present antibodies or fragments thereof also include, for example, leukemia, such as acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemia (e.g., myeloblastic, promyelocytic, myelomonocytic, monocytic, or erythroleukemia), chronic leukemia, chronic myelocytic (granulocytic) leukemia, or chronic lymphocytic leukemia; Polycythemia vera; Lymphoma (e.g., Hodgkin's disease or Non-Hodgkin's disease); multiple myeloma, Waldenstrom's macroglobulinemia; heavy chain disease; solid tumors such sarcomas and carcinomas (e.g., fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, osteosarcoma, chord
  • Th1-lymphocytes e.g., rheumatoid arthritis, multiple sclerosis, psoriasis, Sjorgren's syndrome, Hashimoto's thyroiditis, Grave's disease, primary biliary cirrhosis, Wegener's granulomatosis, tuberculosis, or graft versus host disease
  • Th2-lymphocytes e.g., atopic dermatitis, systemic lupus erythematosus, atopic asthma, rhinoconjunctivitis, allergic rhinitis, Omenn's syndrome, systemic sclerosis, or chronic graft versus host disease.
  • the immunological disorder is a T cell-mediated immunological disorder, such as a T cell disorder in which activated T cells associated with the disorder express CD40.
  • Anti-CD40 antibodies or agents can be administered to deplete such CD40-expressing activated T cells.
  • administration of anti-CD40 antibodies or agents can deplete CD40-expressing activated T cells, while resting T cells are not substantially depleted by the anti-CD40 or agent.
  • “not substantially depleted” means that less than about 60%, or less than about 70% or less than about 80% of resting T cells are not depleted.
  • the present antibody or antigen-binding portion thereof can be administered alone or in combination with one or more other therapeutic agents (e.g., a second therapeutic agent).
  • the pharmaceutical compositions comprising the anti-CD40 antibody or its fragment can further comprise a second therapeutic agent, either conjugated or unconjugated to the antibody or its fragment.
  • the second agent is another monoclonal or polyclonal antibody or antigen-binding portion thereof.
  • the second agent is an immunosuppressant.
  • the second agent is a cytotoxic or cytostatic agent.
  • the second agent may target a receptor or receptor complex other than CD40 on the surface of activated lymphocytes, dendritic cells or CD40-expressing cancer cells.
  • Such combination therapy can have an additive or synergistic effect on condition parameters (e.g., severity of a symptom, the number of symptoms, or frequency of relapse).
  • condition parameters e.g., severity of a symptom, the number of symptoms, or frequency of relapse.
  • the present anti-CD40 antibody or its fragment may be administered concurrently with the second therapeutic agent.
  • the second therapeutic agent is administered prior or subsequent to administration of the anti-CD40 antibody or its fragment.
  • immunosuppressants include, but are not limited to, calcineurin inhibitors (e.g., cyclosporin A (Sandimmune®), cyclosporine G tacrolimus (Prograf®, Protopic®)), mTor inhibitors (e.g., sirolimus (Rapamune®, Neoral®), temsirolimus (Torisel®), zotarolimus, and everolimus (Certican®)), fingolimod (Gilenya®), myriocin, alemtuzumab (Campath®, MabCampath®, Campath-1H®), rituximab (Rituxan®, MabThera®), an anti-CD4 monoclonal antibody (e.g., HuMax-CD4), an anti-LFA1 monoclonal antibody (e.g., CD11a
  • calcineurin inhibitors e.g., cyclosporin A (Sandimm
  • Patent Publication 2006/02807378 monabatacept (Orencia®), belatacept, indolyl-ASC (32-indole ether derivatives of tacrolimus and ascomycin), azathioprine (Azasan®, Imurane®), lymphocyte immune globulin and anti-thymocyte globulin [equine] (Atgam®), mycophenolate mofetil (Cellcept®), mycophenolate sodium (myfortic), daclizumab (Zenapax®), basiliximab (Simulect®), cyclophosphamide (Endoxan®, Cytoxan®, NeosarTM, ProcytoxTM, RevimmuneTM), prednisone, prednisolone, leflunomide (Arava®), FK778, FK779, 15-deoxyspergualin (DSG), busulfan (Myleran®, Busulfex®), fludarabine (Fludar
  • the length of the survival time of the transplanted organ in vivo with and without pharmacological intervention serves as a quantitative measure for the suppression of the immune response.
  • In vitro assays may also be used, for example, a mixed lymphocyte reaction (MLR) assay (see, e.g., Fathman et al., J. Immunol. 118:1232-8, 1977); a CD3 assay (specific activation of immune cells via an anti-CD3 antibody (e.g., OKT3)) (see, e.g., Khanna et al., Transplantation 67:882-9, 1999; Khanna et al.
  • MLR mixed lymphocyte reaction
  • OKT3 anti-CD3 antibody
  • Cyclosporine A (CsA; CAS No. 59865-13-3; U.S. Pat. No. 3,737,433) and its analogs may be used as an immunosuppressant.
  • CsA Cyclosporine A
  • Cyclosporines and their formulations are described, for example, in 2004 Physicians' Desk Reference® (2003) Thomson Healthcare, 58th ed., and U.S. Pat. Nos.
  • Tacrolimus is a macrolide which exerts effects largely similar to CsA, both with regard to its molecular mode of action and its clinical efficacy (Liu, Immunol. Today 14:290-5, 1993; Schreiber et al., Immunol. Today, 13.136-42, 1992); however, these effects are exhibited at doses that are 20 to 100 times lower than CsA (Peters et al., Drugs 46:746-94, 1993).
  • Tacrolimus and its formulations are described, for example, in 2004 Physicians' Desk Reference® (2003) Thomson Healthcare, 58th ed., and U.S. Pat. Nos. 4,894,366; 4,929,611; and 5,164,495.
  • Sirolimus is an immunosuppressive lactam macrolide produceable, for example, by Streptomyces hygroscopicus .
  • Numerous derivatives of sirolimus and its analogs and their formulations are known and described, for example, in 2004 Physicians' Desk Reference® (2003) Thomson Healthcare, 58th ed., European Patent EP 0467606; PCT Publication Nos. WO 94/02136, WO 94/09010, WO 92/05179, WO 93/11130, WO 94/02385, WO 95/14023, and WO 94/02136, and U.S. Pat. Nos.
  • the second agent is a cytotoxic agent which may be a conventional chemotherapeutic such as, for example, doxorubicin, paclitaxel, melphalan, vinca alkaloids, methotrexate, mitomycin C or etoposide.
  • cytotoxic agent such as, for example, doxorubicin, paclitaxel, melphalan, vinca alkaloids, methotrexate, mitomycin C or etoposide.
  • potent agents such as CC-1065 analogues, calicheamicin, maytansine, analogues of dolastatin 10, rhizoxin, and palytoxin can be linked to the anti-CD40 antibodies or agents thereof.
  • the second agent is a humanized anti-HER2 monoclonal antibody; RITUXAN (rituximab; Genentech, Inc., South San Francisco, Calif.); a chimeric anti-CD20 monoclonal antibody); OVAREX (AltaRex Corporation, MA); PANOREX (Glaxo Wellcome, N.C.; a murine IgG2a antibody); ERBITUX (cetuximab) (Imclone Systems Inc., NY; an anti-EGFR IgG chimeric antibody); VITAXIN (MedImmune, Inc., MD); CAMPATH I/H (Leukosite, MA; a humanized IgG1 antibody); Smart M195 (Protein Design Labs, Inc., CA; a humanized anti-CD33 IgG antibody); LymphoCide (Immunomedics, Inc., NJ; a humanized anti-CD22 IgG antibody); Smart ID10 (Protein Design Labs
  • antigens CA125, CA15-3, CA19-9, L6, Lewis Y, Lewis X, alpha fetoprotein, CA 242, placental alkaline phosphatase, prostate specific antigen, prostatic acid phosphatase,
  • the antibodies described herein are useful as affinity purification agents.
  • the antibodies or fragments thereof are immobilized on a solid phase such a Protein A resin, using methods well known in the art.
  • the immobilized antibody or its fragment is contacted with a sample containing the CD40 protein (or fragment thereof) to be purified, and thereafter the support is washed with a suitable solvent that will remove substantially all the material in the sample except the CD40 protein, which is bound to the immobilized antibody. Finally, the support is washed with another suitable solvent that will release the CD40 protein from the antibody.
  • the present anti-CD40 antibodies are also useful in diagnostic assays to detect and/or quantify CD40 protein, for example, detecting CD40 expression in specific cells, tissues, or serum.
  • the antibodies described herein may be employed in any known assay method, such as competitive binding assays, direct and indirect sandwich assays, and immunoprecipitation assays. See, e.g., Zola, Monoclonal Antibodies: A Manual of Techniques, pp. 147-158 (CRC Press, Inc. 1987).
  • the present disclosure provides a composition, e.g., a pharmaceutical composition, containing an antibody, or antigen-binding portion(s) thereof, of The present disclosure, formulated together with a pharmaceutically acceptable carrier.
  • the composition may contain an isolated nucleic acid encoding the present antibody or antigen-binding portion thereof, and a pharmaceutically acceptable carrier.
  • the composition may be effective to reduce the likelihood of, or increase the duration prior to, transplant rejection, to induce immunosuppression, or to treat an autoimmune disorder in a subject.
  • the present composition may be effective in any of the methods described herein.
  • Pharmaceutically acceptable carriers include any and all suitable solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible.
  • the present antibodies (or antigen-binding portion(s) thereof) may be coated in a material to protect the antibodies (or antigen-binding portion(s) thereof) from the action of acids and other natural conditions that may inactivate the antibodies (or antigen-binding portion(s) thereof).
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof.
  • the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
  • the present composition may include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent that delays absorption, for example, monostearate salts and gelatin.
  • compositions of the invention may contain the present antibody or its fragment, and the second therapeutic agent as described herein (e.g., one or more immunosuppressants).
  • the composition may be in the form of a solution, a suspension, an emulsion, an infusion device, or a delivery device for implantation, or it may be presented as a solid form (e.g., a dry powder) to be reconstituted with water or another suitable vehicle before use.
  • a solid form e.g., a dry powder
  • compositions may be in the form of an oil emulsion, water-in-oil emulsion, water-in-oil-in-water emulsion, site-specific emulsion, long-residence emulsion, sticky emulsion, microemulsion, nanoemulsion, liposome, microparticle, microsphere, nanosphere, nanoparticle and various natural or synthetic polymers, such as nonresorbable impermeable polymers such as ethylenevinyl acetate copolymers and Hytrel® copolymers, swellable polymers such as hydrogels, or resorbable polymers such as collagen and certain polyacids or polyesters such as those used to make resorbable sutures, that allow for sustained release of the vaccine.
  • nonresorbable impermeable polymers such as ethylenevinyl acetate copolymers and Hytrel® copolymers
  • swellable polymers such as hydrogels
  • resorbable polymers such as collagen and certain polyacids
  • composition can be in the form of a pill, tablet, capsule, liquid, or sustained release tablet for oral administration; or a liquid for intravenous, intrathecal, subcutaneous or parenteral administration; or a polymer or other sustained release vehicle for local administration.
  • a solution of the composition is dissolved in a pharmaceutically acceptable carrier, e.g., an aqueous carrier if the composition is water-soluble.
  • aqueous solutions include, e.g., water, saline, phosphate buffered saline, Hank's solution, Ringer's solution, dextrose/saline, glucose solutions and the like.
  • the formulations can contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as buffering agents, tonicity adjusting agents, wetting agents, detergents and the like. Additives can also include additional active ingredients such as bactericidal agents, or stabilizers.
  • the solution can contain sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate or triethanolamine oleate.
  • Solid formulations can be used in The present disclosure. They can be formulated as, e.g., pills, tablets, powders or capsules.
  • conventional solid carriers can be used which include, e.g., mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like.
  • Suitable pharmaceutical excipients include e.g., starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk, glycerol, propylene glycol, water, ethanol.
  • the pharmaceutical formulations comprising compositions or nucleic acids, polypeptides, or antibodies of the invention are incorporated in lipid monolayers or bilayers, e.g., liposomes.
  • lipid monolayers or bilayers e.g., liposomes.
  • Aspects of the invention also provide formulations in which water soluble nucleic acids, peptides or polypeptides of the invention have been attached to the surface of the monolayer or bilayer.
  • peptides can be attached to hydrazide-PEG-(distearoylphosphatidyl) ethanolamine-containing liposomes (see, e.g., Zalipsky, Bioconjug.
  • Liposomes or any form of lipid membrane such as planar lipid membranes or the cell membrane of an intact cell, e.g., a red blood cell, can be used.
  • Liposomal formulations can be by any means, including administration intravenously, transdermally (see, e.g., Vutla, J. Pharm. Sci. 85: 5-8, 1996), transmucosally, or orally.
  • the invention also provides pharmaceutical preparations in which the nucleic acid, peptides and/or polypeptides of the invention are incorporated within micelles and/or liposomes (see, e.g., Suntres, J. Pharm. Pharmacol.
  • Liposomes and liposomal formulations can be prepared according to standard methods and are also well known in the art. Akimaru, Cytokines Mol. Ther. 1: 197-210, 1995. Alving, Immunol. Rev. 145: 5-31, 1995. Szoka, Ann. Rev. Biophys. Bioeng. 9: 467, 1980. U.S. Pat. Nos. 4,235,871; 4,501,728 and 4,837,028.
  • compositions are prepared with carriers that will protect the peptide against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems.
  • a controlled release formulation including implants and microencapsulated delivery systems.
  • Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art.
  • Liposomal suspensions can also be used as pharmaceutically acceptable carriers. U.S. Pat. No. 4,522,811.
  • a composition of The present disclosure can be administered by a variety of methods known in the art. As will be appreciated by the skilled artisan, the route and/or mode of administration will vary depending upon the desired results. Administration may be parenteral, intravenous, intrathecal, subcutaneous, oral, topical, local, intramuscular, intradermal, transdermal, subdermal, rectal, spinal, or epidermal. Intravenous delivery by continuous infusion is one exemplary method for administering the present antibodies.
  • the agent may be administered to a subject in an appropriate carrier, for example, liposomes, or a diluent.
  • suitable diluents include saline and aqueous buffer solutions.
  • Liposomes include water-in-oil-in-water CGF emulsions as well as conventional liposomes (Strejan et al., J. Neuroimmunol. 7:27-41, 1984).
  • Parenteral administration can include modes of administration other than enteral and topical administration, usually by injection, and include, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural and intrasternal injection and infusion.
  • aqueous and nonaqueous carriers examples include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate.
  • polyols such as glycerol, propylene glycol, polyethylene glycol, and the like
  • vegetable oils such as olive oil
  • injectable organic esters such as ethyl oleate.
  • Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
  • parenterally administrable compositions will be known or apparent to those skilled in the art and are described in detail. Bai, J. Neuroimmunol. 80: 65-75, 1997. Warren, J. Neurol. Sci. 152: 31-38, 1997. Tonegawa, J. Exp. Med. 186: 507-515, 1997.
  • Formulations for parenteral administration may, for example, contain excipients, sterile water, saline, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, or hydrogenated napthalenes.
  • Biocompatible, biodegradable lactide polymer, lactide/glycolide copolymer, or polyoxyethylene-polyoxypropylene copolymers may be used to control the release of the present agent.
  • Nanoparticulate formulations e.g., biodegradable nanoparticles, solid lipid nanoparticles, liposomes
  • Other potentially useful delivery systems include ethylene-vinyl acetate copolymer particles, osmotic pumps, intrathecal pumps, implantable infusion systems, and liposomes.
  • concentration of the agent in the formulation varies depending upon a number of factors, including the dosage of the drug to be administered, and the route of administration.
  • Sterile injectable solutions can be prepared by incorporating the present agent in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by sterilization microfiltration.
  • dispersions are prepared by incorporating the present agent into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above.
  • the methods of preparation include vacuum drying and freeze-drying (lyophilization) that yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof. Dosage regimens are adjusted to provide the optimum desired response (e.g., a therapeutic response).
  • a single bolus may be administered, several divided doses may be administered over time or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation.
  • the antibodies of the invention may be administered once or twice weekly by subcutaneous injection or once or twice monthly by subcutaneous injection.
  • Parenteral compositions may be formulated in dosage unit form for ease of administration and uniformity of dosage.
  • Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subjects to be treated; each unit contains a predetermined quantity of active agent calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
  • the specification for the dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active agent and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of agenting such an active agent for the treatment of sensitivity in individuals.
  • the present compositions When administered orally, the present compositions may be protected from digestion. This can be accomplished either by complexing the antibody or antigen-binding portion thereof with a composition to render it resistant to acidic and enzymatic hydrolysis or by packaging the antibody or antigen-binding portion thereof in an appropriately resistant carrier such as a liposome. Means of protecting agents from digestion are well known in the art. Fix, Pharm Res. 13: 1760-1764, 1996. Samanen, J. Pharm. Pharmacol. 48: 119-135, 1996. U.S. Pat. No. 5,391,377.
  • penetrants appropriate to the barrier to be permeated can be used in the formulation.
  • penetrants are generally known in the art, and include, e.g., for transmucosal administration, bile salts and fusidic acid derivatives.
  • detergents can be used to facilitate permeation.
  • Transmucosal administration can be through nasal sprays or using suppositories. Sayani, Crit. Rev. Ther. Drug Carrier Syst. 13: 85-184, 1996.
  • the agents are formulated into ointments, creams, salves, powders and gels.
  • Transdermal delivery systems can also include, e.g., patches.
  • compositions can also be administered in sustained delivery or sustained release mechanisms.
  • biodegradable microspheres or capsules or other biodegradable polymer configurations capable of sustained delivery of a peptide can be included in the formulations of the invention (see, e.g., Putney, Nat. Biotechnol. 16: 153-157, 1998).
  • the present compositions can be delivered using any system known in the art, including dry powder aerosols, liquids delivery systems, air jet nebulizers, propellant systems, and the like. Patton, Biotechniques 16: 141-143, 1998. Also can be used in The present disclosure are product and inhalation delivery systems for polypeptide macromolecules by, e.g., Dura Pharmaceuticals (San Diego, Calif.), Aradigm (Hayward, Calif.), Aerogen (Santa Clara, Calif.), Inhale Therapeutic Systems (San Carlos, Calif.), and the like.
  • the pharmaceutical formulation can be administered in the form of an aerosol or mist.
  • the formulation can be supplied in finely divided form along with a surfactant and propellant.
  • the device for delivering the formulation to respiratory tissue is an inhaler in which the formulation vaporizes.
  • Other liquid delivery systems include, e.g., air jet nebulizers.
  • compositions can be administered in a single dose treatment or in multiple dose treatments on a schedule and over a time period appropriate to the age, weight and condition of the subject, the particular composition used, and the route of administration.
  • the frequency of administration can vary depending on any of a variety of factors, e.g., severity of the symptoms, degree of immunoprotection desired, whether the composition is used for prophylactic or curative purposes, etc.
  • the composition according to the invention is administered once per month, twice per month, three times per month, every other week (qow), once per week (qw), twice per week (biw), three times per week (tiw), four times per week, five times per week, six times per week, every other day (qod), daily (qd), twice a day (qid), or three times a day (tid).
  • the duration of administration of a polypeptide according to the invention can vary, depending on any of a variety of factors, e.g., subject response, etc.
  • the composition can be administered over a period of time ranging from about one day to about one week, from about two weeks to about four weeks, from about one month to about two months, from about two months to about four months, from about four months to about six months, from about six months to about eight months, from about eight months to about 1 year, from about 1 year to about 2 years, or from about 2 years to about 4 years, or more.
  • Dosage unit form refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active agent calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
  • Actual dosage levels of the active ingredients in the pharmaceutical compositions of The present disclosure may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
  • the selected dosage level will depend upon a variety of pharmacokinetic factors including the activity of the particular compositions of The present disclosure employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion of the particular agent being employed, the duration of the treatment, other drugs, agents and/or materials used in combination with the particular compositions employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.
  • a physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required.
  • the physician or veterinarian can start doses of the agents of the invention employed in the pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.
  • a suitable daily dose of a composition of the invention will be that amount of the agent which is the lowest dose effective to produce a therapeutic effect.
  • Such an effective dose will generally depend upon the factors described above.
  • the effective daily dose of a therapeutic composition may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms.
  • the dosage of such agents lies within a range of circulating concentrations that include the ED 50 with little or no toxicity.
  • the dosage can vary within this range depending upon the dosage form employed and the route of administration utilized.
  • the therapeutically effective dose can be estimated initially from cell culture assays.
  • a dose can be formulated in animal models to achieve a circulating plasma concentration range that includes the IC 50 (i.e., the concentration of the test agent which achieves a half-maximal inhibition of symptoms) as determined in cell culture.
  • IC 50 i.e., the concentration of the test agent which achieves a half-maximal inhibition of symptoms
  • An exemplary, non-limiting range for a therapeutically or prophylactically effective amount of an antibody or antigen-binding portion of the invention is from about 0.001 to about 100 mg/kg body weight or more, about 0.1 to about 100 mg/kg body weight, about 0.01 to about 80 mg/kg body weight, about 0.001 to about 60 mg/kg body weight, about 0.01 to about 30 mg/kg body weight, about 0.01 to about 25 mg/kg body weight, about 0.5 to about 25 mg/kg body weight, about 0.1 to about 15 mg/kg body weight, about 0.1 to about 20 mg/kg body weight, about 10 to about 20 mg/kg body weight, about 0.75 to about 10 mg/kg body weight, about 1 to about 10 mg/kg body weight, about 2 to about 9 mg/kg body weight, about 1 to about 2 mg/kg body weight, about 3 to about 8 mg/kg body weight, about 4 to about 7 mg/kg body weight, about 5 to about 6 mg/kg body weight, about 8 to about 13 mg/kg body weight, about 8.3 to about 12.5
  • the dosage administered to a subject may also be about 0.1 mg/kg to about 50 mg/kg, about 1 mg/kg to about 30 mg/kg, about 1 mg/kg to about 20 mg/kg, about 1 mg/kg to about 15 mg/kg, or about 1 mg/kg to about 10 mg/kg of the subject's body weight.
  • Exemplary doses include, but are not limited to, from 1 ng/kg to 100 mg/kg.
  • a dose is about 0.5 mg/kg, about 1 mg/kg, about 2 mg/kg, about 3 mg/kg, about 4 mg/kg, about 5 mg/kg, about 6 mg/kg, about 7 mg/kg, about 8 mg/kg, about 9 mg/kg, about 10 mg/kg, about 11 mg/kg, about 12 mg/kg, about 13 mg/kg, about 14 mg/kg, about 15 mg/kg or about 16 mg/kg of the subject's body weight.
  • WO 94/04188 is about 0.5 mg/kg, about 1 mg/kg, about 2 mg/kg, about 3 mg/kg, about 4 mg/kg, about 5 mg/kg, about 6 mg/kg, about 7 mg/kg, about 8 mg/kg, about 9 mg/kg, about 10 mg/kg, about 11 mg/kg, about 12 mg/kg, about 13 mg/kg, about 14 mg/kg, about 15 mg/kg or about 16 mg/kg of the subject's body weight.
  • the composition is formulated to contain an effective amount of the present antibody or antigen-binding portion thereof, wherein the amount depends on the animal to be treated and the condition to be treated.
  • the present antibody or antigen-binding portion thereof is administered at a dose ranging from about 0.01 mg to about 10 g, from about 0.1 mg to about 9 g, from about 1 mg to about 8 g, from about 1 mg to about 7 g, from about 5 mg to about 6 g, from about 10 mg to about 5 g, from about 20 mg to about 1 g, from about 50 mg to about 800 mg, from about 100 mg to about 500 mg, from about 0.01 mg to about 10 g, from about 0.05 ⁇ g to about 1.5 mg, from about 10 ⁇ g to about 1 mg protein, from about 30 ⁇ g to about 500 ⁇ g, from about 40 ⁇ g to about 300 ⁇ g, from about 0.1 ⁇ g to about 200 mg, from about 0.1 ⁇ g to about 5 ⁇ g, from about 5 ⁇ g to about 10 ⁇ g, from
  • the specific dose level for any particular subject depends upon a variety of factors including the activity of the specific peptide, the age, body weight, general health, sex, diet, time of administration, route of administration, and rate of excretion, drug combination and the severity of the particular disease undergoing therapy.
  • an article of manufacture containing materials useful for the treatment of the conditions or disorders described herein comprises a container and a label.
  • Suitable containers include, for example, bottles, vials, syringes, and test tubes.
  • the containers may be formed from a variety of materials such as glass or plastic.
  • the container holds a composition that is effective for treating the condition and may have a sterile access port.
  • the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle.
  • the active agent in the composition may be the humanized anti-CD40 antibody or its fragment, or any other antibody or its fragment as described herein.
  • the label on or associated with the container indicates that the composition is used for treating the condition of choice.
  • the article of manufacture may further comprise a second container comprising a pharmaceutically-acceptable buffer, such as phosphate-buffered saline, Ringer's solution, and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for use.
  • kits containing an anti-CD40 antibody or antigen-binding portion thereof. Additional components of the kits may include one or more of the following: instructions for use; other reagents, a therapeutic agent, or an agent useful for coupling an antibody to a label or therapeutic agent, or other materials for preparing the antibody for administration; pharmaceutically acceptable carriers; and devices or other materials for administration to a subject.
  • the kit may or may not contain the second therapeutic agent as described herein.
  • the agents can be mixed together, or packaged separately within the kit.
  • the kit may or may not contain at least one nucleic acid encoding anti-CD40 antibodies or fragment thereof, and instructions for expression of the nucleic acids.
  • Other possible components of the kit include expression vectors and cells.
  • the present antibody or its fragment can be used in a diagnostic kit, i.e., a packaged combination of reagents in predetermined amounts with instructions for performing the diagnostic assay.
  • the kit may include substrates and cofactors required by the enzyme such as a substrate precursor that provides the detectable chromophore or fluorophore.
  • other additives may be included such as stabilizers, buffers (for example a block buffer or lysis buffer), and the like.
  • the relative amounts of the various reagents may be varied widely to provide for concentrations in solution of the reagents that substantially optimize the sensitivity of the assay.
  • the reagents may be provided as dry powders, usually lyophilized, including excipients that on dissolution will provide a reagent solution having the appropriate concentration.
  • Standard techniques include peptide scanning, in which overlapping, short peptides (for example, 10-30 amino acids, e.g., 20, in length) derived from the full length protein to which the antibody binds are individually tested for their ability to bind the antibody. From such experiments, the region of the protein to which the antibody binds can then be determined.
  • Site-directed mutagenesis can also be used to identify the antigenic region(s) of a particular protein.
  • point mutations are systematically introduced into the target polypeptide and the ability of the antibody to bind the peptide with mutations at various positions is used to determine whether a particular region of that protein contains the epitope to which the antibody binds.
  • Antibody epitopes can also be identified using high-throughput mutagenesis techniques, such as Shotgun Mutagenesis (Integral Molecular, Inc., Philadelphia, Pa.), which can be used to generate large numbers of mutations within the target protein. Such methodologies permit efficient identification of epitopes within the protein.
  • an in vitro competitive blockade assay may be performed.
  • 2C10 was conjugated to allophycocyanin (APC) using the Lightning Link antibody labeling kit (Novus Biologics, Littleton, Colo.).
  • APC allophycocyanin
  • Human PBMCs were incubated with escalating concentrations of 2C10, 3A8, or Chi220, and then stained with the APT-conjugated 2C10 to assess the ability of each antibody to cross-block 2C10.
  • Binding of APC-conjugated 2C10 decreased with increasing concentrations of 2C10 but not Chi220 or 3A8 as shown in FIG. 12 .
  • the result indicates that 2C10 binds a unique epitope distinct from either Chi220 or 3A8.
  • the invention also features fragments of CD40 that include the epitope that is specifically bound by the 2C10 antibody.
  • the 2C10 antibody was raised against the extracellular portion of the CD40 polypeptide.
  • the 2C10 antibody reacts with a portion of this sequence (SEQ ID NOs: 5 and 6).
  • the disclosure therefore features CD40 fragments (e.g., fewer than 150, 120, 100, 80, 70, 60, 50, 40, 30, 20, 18, 15, 12, 11, 10, 9, 8, or 7) amino acids in length that are specifically bound by the 2C10 antibody.
  • the fragment is 8-10, 8-12, 8-15, 8-20, 8-30, 8-40, 8-50, 8-60, 8-70, 8-80, or 8-100 amino acids in length.
  • the fragment is 7-10, 7-12, 7-15, 7-20, 7-30, 7-40, 7-50, 7-60, 7-70, 7-80, or 7-100 in length.
  • the 2C10 antibody binds to an epitope present within the sequence of amino acids 8-10, 8-12, 8-15, 8-20, 8-30, 8-40, 8-50, 8-60, 8-70, 8-80, 8-100, 7-10, 7-12, 7-15, 7-20, 7-30, 7-40, 7-50, 7-60, 7-70, 7-80, or 7-100, of SEQ ID NO: 6.
  • the invention also features fusion protein that includes a fragment described herein and a heterologous sequence.
  • one of the fusion partners is the Fc protein (e.g., mouse Fc or human Fc).
  • the fusion may also be a sequence useful for antibody production, e.g., a maltose binding protein or GST.
  • the fusion protein is a purification or detection tag, for example, proteins that may be detected directly or indirectly such as green fluorescent protein, hemagglutinin, or alkaline phosphatase), DNA binding domains (for example, GAL4 or LexA), gene activation domains (for example, GAL4 or VP16), purification tags, or secretion signal peptides (e.g., preprotyrypsin signal sequence).
  • the fusion partner may be a tag, such as c-myc, poly histidine, or FLAG. Each fusion partner may contain one or more domains, e.g., a preprotrypsin signal sequence and FLAG tag.
  • the CD40 fragments and fusion proteins described herein may be produced by transformation of a suitable host cell with a polynucleotide molecule encoding the polypeptide fragment or fusion protein in a suitable expression vehicle.
  • Exemplary expression systems include prokaryotic hosts (e.g., E. coli ) and eukaryotic hosts (e.g., S. cerevisiae , insect cells, e.g., Sf21 cells, or mammalian cells, e.g., NIH 3T3, HeLa, or preferably COS cells). Such cells are available from a wide range of sources (e.g., the American Type Culture Collection, Manassas, Va.). The method of transformation or transfection and the choice of expression vehicle will depend on the host system selected. Transformation and transfection methods are described, e.g., in Kucherlapati et al. ( CRC Crit. Rev. Biochem.
  • expression vehicles may be chosen from those provided, e.g., in Vectors: Expression Systems: Essential Techniques (ed., Jones, Wiley & Sons Ltd., 1998).
  • CD40 polypeptide fragment or fusion protein Once the recombinant CD40 polypeptide fragment or fusion protein is expressed, it can be isolated, e.g., using affinity chromatography.
  • an antibody specific to CD40 e.g., an antibody or its fragment as described herein
  • Lysis and fractionation of fragment- or fusion protein-harboring cells prior to affinity chromatography may be performed by standard methods (see, e.g., Method in Enzymology , volume 182, eds., Abelson, Simon, and Deutscher, Elsevier, 1990).
  • the CD40 polypeptide fragment or fusion protein can, if desired, be further purified, e.g., by high performance liquid chromatography (see e.g., Fisher, Laboratory Techniques in Biochemistry and Molecular Biology , eds., Work and Burdon, Elsevier, 1980; and Scopes, Protein Purification: Principles and Practice , Third Edition, ed., Cantor, Springer, 1994).
  • the CD40 polypeptide fragments or fusion proteins can also be produced by chemical synthesis (e.g., by the methods described in Solid Phase Peptide Synthesis, 2nd ed., 1984, The Pierce Chemical Co., Rockford, Ill.; and Solid - Phase Synthesis: A Practical Guide , ed., Kates and Albericio, Marcel Dekker Inc., 2000).
  • the present antibodies, antigen-binding portions thereof, compositions and methods can be used in all vertebrates, e.g., mammals and non-mammals, including human, mice, rats, guinea pigs, hamsters, dogs, cats, cows, horses, goats, sheep, pigs, monkeys, apes, gorillas, chimpanzees, rabbits, ducks, geese, chickens, amphibians, reptiles and other animals.
  • vertebrates e.g., mammals and non-mammals, including human, mice, rats, guinea pigs, hamsters, dogs, cats, cows, horses, goats, sheep, pigs, monkeys, apes, gorillas, chimpanzees, rabbits, ducks, geese, chickens, amphibians, reptiles and other animals.
  • mice were immunized with a fusion protein consisting of the extracellular domain of rhesus macaque ( M. mulatta ) CD40 (amino acid sequence: EPPTACREKQYLINSQCCSLCQPGQKLVSDCTEFTETECLPCSESEFLDTWNRETRCHQH KYCDPNLGLRVQQKGTSETDTICTCEEGLHCMSESCESCV; SEQ ID NO:5) fused to maltose binding protein (CD40-MBP).
  • CD40 amino acid sequence: EPPTACREKQYLINSQCCSLCQPGQKLVSDCTEFTETECLPCSESEFLDTWNRETRCHQH KYCDPNLGLRVQQKGTSETDTICTCEEGLHCMSESCESCV; SEQ ID NO:5
  • the amino acid sequence in this region of the rhesus macaque CD40 protein differs from human CD40 protein at five amino acid positions (human amino acid sequence: EPPTACREKQYLINSQCCSLCQPGQKLVSDCTEFTETECLPCGESEFLDTWNRETHCHQH KYCDPNLGLRVQQKGTSETD TICTCEEGWHCTSEACESCV; SEQ ID NO:6).
  • CD40-MBP was administered to mice multiple times with complete Freund's adjuvant and incomplete Freund's adjuvant. Splenocytes from immunized mice were fused with the mouse myeloma cell line SP2/0 and hybrids selected using standard hybridoma technology.
  • Antibodies were selected for reactivity to a second fusion protein consisting of the same rhesus CD40 domain fused to glutamine synthetase (CD40-GST). Antibodies reactive to CD40-GST by ELISA were further tested for reactivity to native CD40 expressed on rhesus macaque blood B cells, human blood B cells and rhesus macaque B-lymphoblastoid cell lines by flow cytometry. As a final level of selection, antibodies were tested in an in vitro assay for their ability to inhibit human or rhesus macaque B cell activation after co-culture CD154-expressing Jurkat D1.1 cells. A stable subclone of anti-CD40 antibody 2C10 was obtained by limiting dilution. The antibody is a mouse IgG1-kappa.
  • variable regions of monoclonal antibodies can be cloned using any method known in the art. PCR-based methods for obtaining antibody variable region sequences for hybridoma cells are described, for example, in Larrick et al., Nat. Biotechnol. 7:934-8, 1989 and in Orlandi et al., Proc. Natl. Acad. Sci. USA 86:3833-7, 1989. Using these techniques or similar techniques, the variable regions of monoclonal antibodies can be cloned and subject to further manipulation. In the present case, the variable sequences from the heavy and light chains of the 2C10 antibody were cloned and were sequenced. The DNA representing the immunoglobulin heavy and light chain variable regions from the 2C10 hybridoma were cloned using 5′ RACE PCR employing the following DNA primers:
  • Mouse kappa reverse (SEQ ID NO: 7) 5′ - CTA ACA CTC ATT CCT GTT GAA GCT CTTGAC; Mouse kappa forward: (SEQ ID NO: 8) 5′ - GCT GAT GCT GCA CCA ACT GTA TCC - 3′
  • Mouse IgG1 reverse (SEQ ID NO: 9) 5′ - GGC AAC GTT GCA GGT CTC GC - 3′
  • Mouse IgG1 forward (SEQ ID NO: 10) 5′ - CTG GAT CTG CCC AAA CTA ACT CC - 3′
  • PCR products were cloned into a commercial cloning vector and were sequenced using standard sequencing techniques. The resulting sequences are provided in FIG. 1 .
  • the immunoglobulin variable region genes were cloned from the hybridomas secreting anti-CD40 antibody clone 2C10 and from anti-human CD40 clone 3A8 (Kwekkeboom et al., Immunology 79:439-44, 1993) (obtained from the American Type Culture Collection, ATCC, Vienna, Va.) using 5′ rapid amplification of cDNA ends-polymerase chain reaction.
  • the immunoglobulin heavy and light chain variable regions were subcloned into expression vectors containing rhesus IgG1 or rhesus IgG4 heavy chain and rhesus kappa light chain constant region sequences.
  • Recombinant heavy and light chains were subcloned into expression vectors and packaged in retroviral vectors used to transduce Chinese hamster ovary cells using the GPExTM expression technology (Catalent Pharma Solutions, Middleton, Wis.).
  • a pool of transduced cells was grown in serum-free medium and secreted antibody was purified by protein A affinity chromatography.
  • the purified chimeric rhesus IgG1 (2C10R1, 3A8R1) and IgG4 (2C10R4) antibodies were diafiltered into phosphate buffer, endotoxin levels were confirmed to be less than 1 endotoxin unit/mg.
  • CD154, rhesus and human B cells were incubated with escalating concentrations of 2C10 or an isotype control and then incubated with histidine-tagged soluble CD154 (R&D Systems, Minneapolis, Minn.) and analyzed for histidine expression.
  • 2C10 blocked the binding of CD154 in a dose-dependent manner ( FIG. 3 ), indicating that 2C10 can effectively block the interaction of T cell-bound CD154 with CD40 on B cells and antigen-presenting cells.
  • the anti-CD40 antibody 2C10 was characterized with respect to its ability to affect B cell activation both using rhesus monkey and human peripheral blood mononuclear cells (PBMCs).
  • CD20 expression was chosen as being an indicator of B cells, and expression of CD23, CD80, and CD86 is associated with B cell activation.
  • 2C10 was first assessed for its ability to bind to CD20.
  • Rhesus or human PBMCs were incubated with fluorochrome-conjugated 2C10 and an anti-CD20 antibody. Flow cytometric analysis was used to confirm the binding of 2C10 to human and rhesus CD20+ B cells ( FIG. 2A ).
  • PBMCs from either rhesus monkey or humans were cultured either in the presence or absence of CD154 + Jurkat D1.1 cells, an immortalized T lymophocyte cell line. Activation of B cells was determined by measuring expression of three markers (CD23, CD80, and CD86) in CD20+ cells present in the PBMCs. The general scheme of this assay is shown in FIG. 4 . As shown in FIG. 4 , culturing PBMCs in the presence of Jurkat cells resulted in increased expression of all three markers, indicating that B cells are activated by the CD154 + Jurkat cells.
  • PBMCs and Jurkat cells were co-cultured in the presence or absence of one of three antibodies: 3A8, 5C8, and 2C10.
  • the 3A8 antibody is a mouse anti-human CD40 antibody (ATCC Deposit No. HB-12024), and 5C8 is an anti-CD154 antibody (ATCC Deposit No. CRL-10915).
  • 3A8 antibody is a mouse anti-human CD40 antibody (ATCC Deposit No. HB-12024)
  • 5C8 is an anti-CD154 antibody (ATCC Deposit No. CRL-10915).
  • Co-cultures were conducted over a range of five orders of magnitude of antibody concentration (0.001 ⁇ g to 10 ⁇ g). As shown in FIG.
  • 3A8 did not block B cell activation in rhesus PBMCs, as measured by CD23 expression, whereas both 2C10 and 5C8 were able to block activation with similar efficiency. Corresponding changes were also observed with CD80 and CD86 expression. These results indicate that 2C10 binds to a different epitope on CD40 than 3A8. These results also indicate that 2C10 acts primarily as a CD40 antagonist in contrast to 3A8 which has previously been shown to act as partial agonists with weak stimulatory potential (Adams et al., J. Immunol. 174:542-50, 2005, Badell et al., Am. J. Transplant . accepted for publication, 2011).
  • the 2C10 and 3A8 antibodies were also tested for their ability to activate B cells in the absence of Jurkat cells using either rhesus monkey or human PBMCs.
  • PBMCs were cultured either in the presence or absence of either 2C10 or 3A8.
  • Expression of CD23, CD80, and CD86 was then measured in CD20 + cells.
  • CD23 expression in rhesus cells was increased in the presence of the 3A8, but not the 2C10, antibody.
  • neither 3A8 nor 2C10 activated human B cells.
  • the differences in activity observed between the 3A8 and 2C10 antibody indicate that the 2C10 antibody binds to an epitope different from that of the 3A8 antibody.
  • 2C10 binds to a unique epitope on CD40, inhibits B cell activation similarly to an anti-CD154 antibody, and lacks agonistic properties
  • Recombinant mouse-rhesus chimeric forms of 2C10 were generated using either rhesus IgG (2C10R1) or IgG4 (2C10R4) heavy chain and rhesus kappa light chain constant region sequences.
  • a chimeric rhesus IgG1 form of 3A8 (3A8R1) was also generated for use as a control.
  • T cell-dependent antibody responses to KLH-NP were tested by ELISA. Plates were coated with KLH (0.01 mg/ml, Sigma, St. Louis, Mo.) and blocked with Super Block (Thermo Scientific, Woodstock, Ga.). Pre- and post-treatment plasma samples were serially diluted, plated for 1 hr, and washed with phosphate-buffered saline/0.05% Tween. Anti-KLH antibodies were detected by incubating for 1 hr with monoclonal anti-rhesus IgG-horseradish peroxidase (clone 1B3, NHP Reagent Resource, Boston, Mass.). Plates were then incubated with Peroxidase Substrate Solution (KPL).
  • KPL Peroxidase Substrate Solution
  • the digested pancreas was purified on a four layer, discontinuous Euroficoll gradient (Mediatech, Manassas, Va.) and Cobe 2991 blood cell processor (CaridianBCT, Lakewood, Colo.). Samples of the final islet preparation were counted and expressed as islet equivalents (IEQ). Isolated islets were cultured overnight, counted and suspended in Transplant Media (Mediatech).
  • Rhesus macaques weighing 3-5 kg were rendered diabetic using streptozotocin (1250 mg/m 2 IV; Zanosar, Teva Parenteral Medicines, Irvine, Calif.) four weeks prior to transplantation. Diabetes was confirmed by intravenous glucose tolerance test (IVGTT) with a 500 mg/kg bolus of dextrose and measurement of primate C-peptide. Glucose levels were monitored and C-peptide was measured at baseline and 10, 30, 60 and 90 after injection of dextrose. Diabetes was confirmed by measurement of elevated blood glucose levels in the absence of detectable serum C-peptide. Diabetic recipients underwent MHC-mismatched islet allotransplantation. A mean of 15,745 ( ⁇ 4,063) IEQ were infused via a small midline laparotomy and cannulation of a mesenteric vein.
  • Blood glucose levels were measured twice daily by earstick; NPH (Novolin; Novo Nordisk, Princeton, N.J.) and glargine (Lantus; Sanofi-Aventis, Bridgewater, N.J.) insulin were administered to maintain fasting blood glucose (FBG) less than 300 mg/dL pre-transplant and following graft rejection.
  • IVGTT was performed periodically post-transplant to monitor graft function.
  • Transplant recipients underwent weekly flow cytometric analysis to monitor T cell (CD3 V450, CD4 PerCP-Cy5.5, CD8 PerCp; BD Bioscience) and B cell (CD20 PE, BD Bioscience) populations. After islet engraftment rejection was defined as FBG greater than 130 mg/dL on two consecutive days. Primary endpoint was rejection-free islet graft survival.
  • Transplant recipients received either 2C10R4, basiliximab (Simulect, Novartis, Basel, Switzerland) and sirolimus, or basiliximab and sirolimus alone.
  • 2C10R4 50 mg/kg was administered intravenously on post-operative day (POD) 0 and 7.
  • Basiliximab 0.3 mg/kg was administered intravenously on POD 0 and 3.
  • Sirolimus was administered intramuscularly daily to achieve trough levels of 5-15 ng/ml through POD 120. All three animals receiving basiliximab and sirolimus alone are historic controls (Badell et al., J. Clin. Invest. 120:4520-312, 2010). Two of these historic controls (RQz6 and RIb7) underwent diabetes induction by pancreatectomy and received oral sirolimus.
  • FIG. 11A Treatment with the regimens described above resulted in significantly prolonged islet graft survival ( FIG. 11A ) compared to controls receiving only basiliximab induction and sirolimus maintenance therapy ( FIG. 11B ).
  • Pharmacokinetic data predict that plasma 2C10R4 levels would be less than 1 ⁇ g/ml by POD 100. Because sirolimus was discontinued at POD120, the recipient with the longest survival (304 days) received no immunosuppression for approximately 24 weeks prior to rejection. No animals treated with 2C10R4 developed clinically relevant infectious complications or weight loss.
  • Blockade of the CD40/CD154 pathway may prove useful in conjunction with other costimulation blockade agents.
  • Belatacept a high affinity version of CTLA4-Ig designed to block the CD28/B7 costimulatory pathways, has shown efficacy in nonhuman primate models of renal and islet transplantation and in phase II and Ill clinical trials in renal transplantation (Larsen et al., Transplantation 90:1528-35, 2010, Vincenti et al., Am. J. Transplant. 10:535-46, 2010, Adams et al., J. Immunol. 174:542-50, 2005, Adams et al., Diabetes 51:265-70, 2002, Larsen et al., Am. J. Transplant.
  • h2C10 humanized 2C10 antibody
  • the binding epitopes were carefully designed to confer unique binding properties that distinguish it from competitor molecules that either activate or deplete B cells or acts as partial agonists.
  • the early mouse primate chimeric version of the antibody has been investigated in relevant preclinical in vitro and in vivo studies, including multiple studies in nonhuman primates that demonstrate promising efficacy against preventing transplant rejection and prolonging both allo- and xenograft survival, and a favorable nonclinical safety profile, We have also completed the humanization of 2C10 (h2C10), which exhibits excellent characteristics.
  • variable region sequences of the murine antibody 2C10 were used to search the human antibody database.
  • the VH was found to be mostly related to germline antibody sequences VH1-46, VH1-69, and VH1-3 (SEQ ID NO: 30), whereas the VL was mostly related to germline antibody sequences VK3-11 (SEQ ID NO: 31), VK1-39, and VK6-21.
  • the human VH1-3 and VK3-11 were chosen to be the acceptor framework for CDR grafting because of relative high usage in human repertoire and good conservation at the critical framework positions. 3D models were built with both variable regions after grafting the CDRs from the murine 2C10 antibody into the human acceptor frameworks.
  • the parental murine 2C10 antibody was humanized by CDR grafting.
  • the human antibody VH1-3 and VK3-11 germline frameworks were chosen to be the acceptor.
  • Three VH and two VL sequences were designed and all 6 humanized antibodies were produced and tested for human CD40 binding.
  • the 2C10-heavy-3 (2C10_h3) and 2C10-light-2 (2C10_12) constructs were found to produce the best antibody with CD40 binding affinity of 0.39 nM, within 2-fold of that of the murine 2C10 (0.22 nM) (Table 2).
  • the humanized variable regions were used to construct the clinical candidate humanized antibody as an IgG4 or a stabilized IgG4, which was cloned into the SwiMR expression system.
  • High producing stable CHO cell lines were isolated by FACS and screened by three rounds of ELISA and one round of fed-batch culture. Seven clones were isolated that produced more than 0.8 g/L of humanized 2C10 in a fed-batch culture. The best clone 3C9-16 produced ⁇ 1.2 g/L under non-optimized conditions.
  • the humanized VH sequences were gene synthesized and cloned into vector pFUSE-CHIg-hG2a (Invivogen) containing the constant region of human IgC2 heavy chain to make expression vector LB300-302.
  • the humanized VK sequences were gene synthesized and cloned into an expression vector containing the constant region of human kappa light chain to make expression vector LB303-304.
  • the heavy and light chains were downstream of human EF1 ⁇ promoter for strong and constitutive mammalian cell expression.
  • the chimeric 2C10 antibody was also constructed similarly by using murine VH and VL to make expression vector LB305 and LB306, respectively.
  • the antibody expression vectors were summarized in Table 4.
  • Each vector in Table 4 contains a heavy chain or light chain expression cassette under the control of human EF1a promoter.
  • Vectors LB300-302, LB305 contain the constant region of human IgG2 heavy chain.
  • Vectors LB308-309 contain the constant region of human IgG4 heavy chain.
  • Vectors LB303-304, LB306 contain the constant region of human Kappa light chain.
  • the humanized antibody with the best binding activity (2C10_h3 and 2C10_12) was converted into human IgG4 or stabilized human IgG4 (S241P).
  • the heavy chain variable region 2C10_h3 was first cloned into vector pFUSE-CHIg-hG4 (Invivogen) containing the constant region of human IgG4 heavy chain, before the stabilizing mutation S241P was introduced (Table 4).
  • the humanized IgG4 and IgG4 (S24IP) were purified from 293F cells after transient transfection. The production yield was 25-35 mg/L, 2-fold higher than that of the IgG2 antibodies.
  • the IgG4 antibody appeared to have small amount of half molecule, which was significantly reduced in the stabilized IgG4 antibody.
  • the DNA and amino acid sequence of the stabilized IgG4 antibody is shown in FIG. 21 .
  • SwiMR expression was developed for facile development of antibody production cell lines, utilizing a switchable membrane reporter to facilitate isolation of highly productive cells via Fluorescence-activated cell sorting (FACS).
  • FACS Fluorescence-activated cell sorting
  • An IRES-mediated bicistronic expression cassette of membrane-anchored GFP was placed downstream of the gene of interest (GOI).
  • the IRES-GFP cassette was flanked by LoxP sites for later removal from the chromosome.
  • the GFP expression level was used to mark the expression level of the GOI.
  • Highly productive cells were isolated by FACS and then treated with Cre recombinase to remove the GFP cassette.
  • the humanized 2C10 in the stabilized IgG4 format was cloned the SwiMR expression system to make vector LB312.
  • the heavy and light chains were cloned in two separate expression cassettes under control of human EF1 ⁇ promoters.
  • the IRES-GFP cassette was placed downstream of the heavy chain sequence and was flanked by two LoxP sites.
  • the plasmid carries a Puromycin resistant gene for mammalian cell selection and a ⁇ -lactamase gene for bacterial propagation.
  • CHOS cells 100 ml of CHOS cells (1 ⁇ 10 6 cells/ml, Invitrogen) were transfected with 120 ug of LB312 linearized by restriction digestion of Asc I and 120 ul of Freestyle Max regent (Invitrogen). The cells were selected with 10-20 ug/ml of Puromycin for 2 weeks.
  • the GFP expression profile of the stable pool was characterized by flow cytometry. The top 1% of the cells with the highest GFP signal was sorted out as Pool #1 containing 100,000 cells. After culturing for 2 weeks, the Pool #1 was analyzed again for GFP expression by flow cytometry. The top 1% of the cells with the highest GFP signal was sorted out again as Pool #2 containing 100,000 cells.
  • the Pool #2 was treated with 2 uM of recombinant membrane permeable DNA recombinase Cre (TAT-NLS-Cre, Excellgen).
  • TAT-NLS-Cre recombinant membrane permeable DNA recombinase Cre
  • the GFP expression profile was analyzed after 1 week of culturing ⁇ 10% of the cells completely lost the GFP expression indicating successful removal of the GFP expression cassette from the chromosome.
  • the GFP negative cells were sorted out as single cells in 384-well plates. After 2 weeks, ⁇ 800 colonies grew out from 10 ⁇ 384-w plates.
  • Humanized antibodies were also generated using two CDR grafted VH and two CDR grafted VL sequences cloned into a VH1-69 and a VL1-39 human germline framework. We made two heavy (HB1 & HB2) and two light (KB1 & KB2) chains in these additional experiments. The heavy and light chain sequences HP+KP serves as the positive control. The combination of these constructs was transiently expressed in HEK293 cells, antibody purified by protein-A chromatography and tested for hCD40 binding.
  • FIG. 14 shows amino acid changes in framework 3 between 2C10HP and 2C10HB1, as well as 2C10HB2 constructs.
  • FIG. 15 shows the sequences of heavy chain and light chain variable regions for humanized 2C10 antibodies.
  • the heavy chain and light chain variable regions include 2C10HP, 2C10HB1, 2C10HB2, 2C10KP, 2C10KB1, and 2C10KB2. Therefore, in certain embodiments, an anti-CD40 antibody may include any of the following 2C10H-K combinations;
  • Humanized antibodies and the chimeric antibody were purified after transient transfection of 100 or 200 ml of 293F cells.
  • the antibodies were purified with a Protein A column from the conditioned media harvested 4 days after transfection.
  • CD40 binding kinetics was determined on Forte Bio (contracted to Aragen Bioscience). The purified CD40 was biotinylated and immobilized on Streptavidin biosensors.
  • the antibody was purified by Protein A column, and followed by buffer exchange (20 mM Sodium Citrate, 50 mM NaCl, 5% Maltose, pH 6.0) and 0.2 ⁇ m filtration.
  • the Pool #1 was used to setup 25 L wave bag culture in CD FortiCHO media (Invitrogen). The culture was fed three times on day 3, 5, and 7 with 10% CD Efficient Feed C (Invitrogen). The final yield of purified antibody was 1.6 g in total.
  • the antibody was characterized by SDS-PAGE and SEC-HPLC analysis, and was 99.4% pure as monomeric antibody.
  • the single cell colonies were screened by 3 rounds of ELISA and 1 round of fed-batch production.
  • the cells were kept in CD FortiCHO media throughout the screening process. All colonies from 384-well plates were picked into 96-well plates. 1.2 ⁇ l of culture media from each well were used to screen for antibody in ELISA plates coated with anti-human Fc antibody.
  • the top 240 clones were expanded into 10 ⁇ 24-well plates. After culturing for 5 days, 1.2 td of culture media was screened again for antibody level, the top 60 clones were expanded into 10 ⁇ 6-well plates and cultured in shaking incubator. After culturing for 5 days, the 6-well plates were duplicated by passaging the cells 1:10 into a new set of 6-well plates.
  • the cultures in the original set of the 6-well plates were allowed to grow to extinction, followed by determination of antibody level by ELISA.
  • the top 24 clones in the duplicated set of 6-well plates were expanded into 30 ml culture in 125 ml shake flasks. The clones were subjected to 30 ml fed-batch production.
  • the feeding strategy was 7.5% of Ex-Cell Advanced CHO Feed 1 (Sigma) on day 3, 5, 7, 9, and 11.
  • the top clone 3C9-I6 exhibited production titer of ⁇ 1.2 g/L.
  • the 2C10 mAb was humanized by CDR grafting into a human heavy and light chain frameworks.
  • the humanized 2C10 constructs were screened by Biacore for affinity to human CD40. All three top humanized 2C10 antibodies exhibited only slight reduction in affinity by approximately two-fold, relative to the parent 2C10 mAb (Table 5). Most importantly they all maintained the exceptional slow off rate of the parent 2C10 mAb.
  • Clone 2.189.2 which exhibited the highest affinity at 390 pM, was selected as the lead humanized mAb (h2C10).
  • h2C10 Comparing the binding kinetics of humanized 2C10 to competitors, the overall affinity of h2C10 remains substantially better than the competitors that have affinities in the nanomolar range.
  • h2C10 may be used for treatment of conditions in which selective blockade of CD40 receptor activation in the absence of B cell depletion is expected to provide therapeutic benefit.
  • h2C10 blocks T-cell dependent antibody responses (TDAR) in vivo
  • monkeys were immunized with KLH 6 hours after the administration of h2C10.
  • Antibody titers against KLH were measured weekly thereafter.
  • FIG. 17 shows that the humanized version of 2C10 achieved complete inhibition of the KLH antibody response at the highest test dose, and in most cases at the 10 mg/kg dose level. Both IgM and IgG responses were prevented.
  • CD40 antibody As goals in the development of an antagonist CD40 antibody included minimizing the depletion of targeted, CD40+ cells, we analyzed effects on lymphocyte subpopulations, especially the effect on B cells.
  • CD40 target engagement and occupancy by the primate chimeric and humanized versions of 2C10 was determined by measuring the available binding sites for 2C10 to CD40 on CD20+ B cells by flow cytometry using fluorescently labeled 2C10 and a labeled, non-competing anti-CD40 antibody. Blood samples were collected on multiple days from control monkeys and monkeys treated with either primate chimeric IgG4 or humanized 2C10 and analyzed by FACS. The degree of target engagement (% receptor occupancy) was calculated directly from the mean fluorescent intensity recordings.
  • Humanized 2C10 antibodies were administered intravenously at single doses of 10 and 25 mg/kg. Surface CD40 on B cells was completely saturated by Day 3, and the effect persisted until the last day measured (Day 28) in all monkeys that received either dose of h2C10. Representative data from the flow cytometry analysis of blood collected from monkeys 28 days after treatment with humanized 2C10 is shown FIG. 19 .
  • plasma concentrations of the 2C10 were measured in plasma from the same blood samples in which receptor occupancy had been determined.
  • the plasma concentration analysis also enabled characterization of the pharmacokinetic profile of 2C10, most importantly its persistence in plasma as determined by its half-life. This determination provides guidance for the frequency of dosing that will be needed to maintain effective therapeutic concentrations.
  • the mean serum concentrations determined in monkeys treated with either 10 or 25 mg/kg humanized 2C10 are plotted in FIG. 20 .
  • These data demonstrate that the animals were exposed to 2C10 for the entire duration of the study, and that humanized 2C10 has a half-life in monkeys of approximately 15 days (ranging from 9-20 days). This half-life is in the range of that expected for a therapeutic antibody in primates, and should support a relatively infrequent dosing schedule in clinical investigations (e.g., no more than once every two weeks). Further modeling of the complete dataset will enable a robust estimate of the dose and frequency required to sustain effective antibody concentrations in initial clinical studies of h2C10.
  • h2C10 Another assessment of humanized 2C10 was the potential development of antibodies against h2C10 (ADA). This can occur when biologics of epitopes from one species is administered to a different species (eg. Humanized mAb to primates) resulting in rapid clearance of the drug from plasma. In this study there was no evidence from the time course profile that antibodies against h2C10 were generated, as no animal exhibited measurable anti-2C10 titers during the study.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
US15/829,352 2015-09-04 2017-12-01 Humanized anti-CD40 antibodies and methods of administering thereof Active US9974855B2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US15/829,352 US9974855B2 (en) 2015-09-04 2017-12-01 Humanized anti-CD40 antibodies and methods of administering thereof
US15/955,393 US10201608B2 (en) 2015-09-04 2018-04-17 Polynucleotides encoding humanized anti-CD40 antibodies
US16/234,110 US10772958B2 (en) 2015-09-04 2018-12-27 Humanized anti-CD40 antibodies and methods of administering thereof
US16/994,249 US11439706B2 (en) 2015-09-04 2020-08-14 Polynucleotides encoding a humanized anti-CD40 antibody
US17/818,188 US20220387587A1 (en) 2015-09-04 2022-08-08 Humanized anti-cd40 antibodies and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562214411P 2015-09-04 2015-09-04
PCT/US2016/050114 WO2017040932A1 (en) 2015-09-04 2016-09-02 Humanized anti-cd40 antibodies and uses thereof
US15/829,352 US9974855B2 (en) 2015-09-04 2017-12-01 Humanized anti-CD40 antibodies and methods of administering thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/050114 Continuation WO2017040932A1 (en) 2015-09-04 2016-09-02 Humanized anti-cd40 antibodies and uses thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US15/955,393 Division US10201608B2 (en) 2015-09-04 2018-04-17 Polynucleotides encoding humanized anti-CD40 antibodies
US15/955,393 Continuation US10201608B2 (en) 2015-09-04 2018-04-17 Polynucleotides encoding humanized anti-CD40 antibodies

Publications (2)

Publication Number Publication Date
US20180078640A1 US20180078640A1 (en) 2018-03-22
US9974855B2 true US9974855B2 (en) 2018-05-22

Family

ID=58188471

Family Applications (5)

Application Number Title Priority Date Filing Date
US15/829,352 Active US9974855B2 (en) 2015-09-04 2017-12-01 Humanized anti-CD40 antibodies and methods of administering thereof
US15/955,393 Active US10201608B2 (en) 2015-09-04 2018-04-17 Polynucleotides encoding humanized anti-CD40 antibodies
US16/234,110 Active US10772958B2 (en) 2015-09-04 2018-12-27 Humanized anti-CD40 antibodies and methods of administering thereof
US16/994,249 Active 2036-09-28 US11439706B2 (en) 2015-09-04 2020-08-14 Polynucleotides encoding a humanized anti-CD40 antibody
US17/818,188 Pending US20220387587A1 (en) 2015-09-04 2022-08-08 Humanized anti-cd40 antibodies and uses thereof

Family Applications After (4)

Application Number Title Priority Date Filing Date
US15/955,393 Active US10201608B2 (en) 2015-09-04 2018-04-17 Polynucleotides encoding humanized anti-CD40 antibodies
US16/234,110 Active US10772958B2 (en) 2015-09-04 2018-12-27 Humanized anti-CD40 antibodies and methods of administering thereof
US16/994,249 Active 2036-09-28 US11439706B2 (en) 2015-09-04 2020-08-14 Polynucleotides encoding a humanized anti-CD40 antibody
US17/818,188 Pending US20220387587A1 (en) 2015-09-04 2022-08-08 Humanized anti-cd40 antibodies and uses thereof

Country Status (17)

Country Link
US (5) US9974855B2 (ja)
EP (2) EP3307322B1 (ja)
JP (3) JP6976931B2 (ja)
KR (1) KR20180044422A (ja)
CN (2) CN116063481A (ja)
AU (2) AU2016315873B2 (ja)
BR (1) BR112018004296B1 (ja)
CA (1) CA3002789A1 (ja)
DK (1) DK3307322T3 (ja)
ES (1) ES2887602T3 (ja)
HK (1) HK1251974A1 (ja)
HU (1) HUE056769T2 (ja)
MX (2) MX2018002708A (ja)
PL (1) PL3307322T3 (ja)
PT (1) PT3307322T (ja)
SI (1) SI3307322T1 (ja)
WO (1) WO2017040932A1 (ja)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10201608B2 (en) * 2015-09-04 2019-02-12 Primatope Therapeutics Inc. Polynucleotides encoding humanized anti-CD40 antibodies
US10561728B2 (en) 2011-03-11 2020-02-18 Beth Israel Deaconess Medical Center, Inc. Polynucleotides encoding anti-CD40 antibodies
US11396552B2 (en) 2018-02-12 2022-07-26 Diabetes-Free Inc. Antagonistic anti-human CD40 monoclonal antibodies

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107249318A (zh) 2014-12-10 2017-10-13 明尼苏达大学董事会 用于治疗疾病的遗传修饰的细胞、组织和器官
CN109475602B (zh) 2016-06-20 2023-05-16 科马布有限公司 抗pd-l1和il-2细胞因子
MX2019007144A (es) 2016-12-19 2019-10-07 Glenmark Pharmaceuticals Sa Nuevos agonistas de tnfr y sus usos.
US11525005B2 (en) 2017-06-01 2022-12-13 Jiangsu Hengrui Medicine Co., Ltd. Anti-CD40 antibody, antigen binding fragment thereof and medical use thereof
BR112021001083A2 (pt) 2018-07-20 2021-05-11 Eucure (Beijing) Biopharma Co., Ltd anticorpos anti-cd40 e usos dos mesmos
CA3120793A1 (en) 2018-11-30 2020-06-04 Jiangsu Hengrui Medicine Co., Ltd. Anti-cd40 antibody, antigen binding fragment and pharmaceutical use thereof
TW202021620A (zh) 2018-11-30 2020-06-16 大陸商江蘇恒瑞醫藥股份有限公司 一種cd40抗體藥物組合物及其用途
CN113474012B (zh) * 2019-01-25 2023-09-08 湖南远泰生物技术有限公司 Epcam抗体和epcam-car-t细胞
EP3954705A4 (en) * 2019-04-10 2023-06-07 Nankai University ANTI-CD40 ANTIBODIES AND ITS USE
MX2021013631A (es) * 2019-05-08 2022-04-12 Novartis Ag Anticuerpos anti-cd40 para el uso en el tratamiento de t1dm e insulitis.
US11434291B2 (en) 2019-05-14 2022-09-06 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
WO2020253722A1 (en) * 2019-06-17 2020-12-24 Eucure (Beijing) Biopharma Co., Ltd Anti-cd40 antibodies and uses thereof
AU2019465294A1 (en) * 2019-09-11 2022-03-24 Novartis Ag A method for preventing human virus associated disorders in patients
EP4153630A1 (en) * 2020-05-18 2023-03-29 Bristol-Myers Squibb Company Antibody variants with improved pharmacokinetic properties
WO2021252917A2 (en) 2020-06-11 2021-12-16 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
WO2023274007A1 (zh) * 2021-06-29 2023-01-05 舒泰神（北京）生物制药股份有限公司 特异性识别cd40的抗体及其应用
CN115812082A (zh) * 2021-07-14 2023-03-17 舒泰神（北京）生物制药股份有限公司 特异性识别cd40的抗体及其应用
JP2023058903A (ja) * 2021-10-14 2023-04-26 株式会社三共 遊技機
JP2023058900A (ja) * 2021-10-14 2023-04-26 株式会社三共 遊技機
JP2023058901A (ja) * 2021-10-14 2023-04-26 株式会社三共 遊技機
JP2023058902A (ja) * 2021-10-14 2023-04-26 株式会社三共 遊技機
JP2023058899A (ja) * 2021-10-14 2023-04-26 株式会社三共 遊技機
KR20240095255A (ko) * 2021-11-05 2024-06-25 키닉사 파마슈티컬스, 게엠베하 인간화 항-cd40 항체의 약학적 조성물
EP4426743A1 (en) * 2021-11-05 2024-09-11 Kiniska Pharmaceuticals, GmbH Pharmaceutical compositions of humanized anti-cd40 antibodies and uses thereof
WO2023133577A1 (en) * 2022-01-10 2023-07-13 Kiniksa Pharmaceuticals, Ltd. Methods of treating or reducing risk of transplant rejection
US20240190978A1 (en) 2022-11-15 2024-06-13 CSBioAsset LLC Compositions and methods for immunomodulatory bifunctional fusion molecules

Citations (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677165A (en) 1992-07-09 1997-10-14 Chiron Corporation Anti-CD40 monoclonal antibodies capable of blocking B-cell activation
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
US6280957B1 (en) 1998-02-04 2001-08-28 The General Hospital Corporation Costimulatory blockade and mixed chimerism in allo-transplantation
WO2001098357A2 (en) 2000-06-19 2001-12-27 Beth Israel Deaconess Medical Center Compositions and methods of monoclonal and polyclonal antibodies specific for t cell subpopulations
US20020031512A1 (en) 2000-04-19 2002-03-14 M. C. Pasch CD40 antagonists for use in treating psoriasis and other inflammatory skin conditions
WO2003040170A2 (en) 2001-11-09 2003-05-15 Pfizer Products Inc. Antibodies to cd40
US20040110226A1 (en) 2002-03-01 2004-06-10 Xencor Antibody optimization
WO2005044307A2 (en) 2003-11-04 2005-05-19 Chiron Corporation Methods of therapy for b cell-related cancers
WO2005044854A2 (en) 2003-11-04 2005-05-19 Chiron Corporation Antagonist anti-cd40 monoclonal antibodies and methods for their use
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
US7193064B2 (en) 2001-04-27 2007-03-20 Kirin Beer Kabushiki Kaisha Anti-CD40 monoclonal antibody
WO2007053767A1 (en) 2005-11-01 2007-05-10 Novartis Ag Uses of anti-cd40 antibodies
WO2007053661A2 (en) 2005-11-01 2007-05-10 Novartis Ag Uses of anti-cd40 antibodies
US20070110754A1 (en) 2003-11-04 2007-05-17 Chiron Corporation Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia
WO2008118356A2 (en) 2007-03-22 2008-10-02 Biogen Idec Ma Inc. Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
WO2009062054A1 (en) 2007-11-09 2009-05-14 Novartis Ag Uses of anti-cd40 antibodies
US20090304706A1 (en) 2006-04-21 2009-12-10 Novartis Ag Antagonist anti-cd40 antibody pharmaceutical compositions
US20090311268A1 (en) 2000-02-01 2009-12-17 Pangenetics Bv Cd40-binding activating antibodies
WO2010065819A1 (en) 2008-12-05 2010-06-10 Als Therapy Development Institute Method for the treatment of neurodegenerative diseases
US20100239575A1 (en) 2009-03-10 2010-09-23 Baylor Research Institute Anti-cd40 antibodies and uses thereof
US20110027276A1 (en) 2008-01-23 2011-02-03 Xencor ,Inc. Optimized CD40 Antibodies and Methods of Using the Same
US20110243932A1 (en) 2010-03-31 2011-10-06 Boehringer Ingelheim International Gmbh Anti-cd40 antibodies
US8106164B2 (en) 2004-06-21 2012-01-31 Bioarctic Neuroscience Ab Antibodies specific for soluble amyloid beta peptide protofibrils and uses thereof
US8138134B2 (en) 2006-09-29 2012-03-20 Union Carbide Chemicals & Plastics Technology Llc Quaternized cellulose ethers for personal care products
WO2012065950A1 (en) 2010-11-15 2012-05-24 Novartis Ag Silent fc variants of anti-cd40 antibodies
US8226952B2 (en) 2005-02-02 2012-07-24 University Of Massachusetts Human antibodies against rabies and uses thereof
WO2012111762A1 (ja) 2011-02-17 2012-08-23 協和発酵キリン株式会社 抗ｃｄ４０抗体の高濃度製剤
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
US8303955B2 (en) 2005-05-26 2012-11-06 Seattle Genetics, Inc. Humanized anti-CD40 antibodies and their methods of use
EP1707627B1 (en) 2003-12-25 2012-11-14 Kyowa Hakko Kirin Co., Ltd. Antagonistic anti-CD40 antibody mutant
US20140093497A1 (en) 2011-03-11 2014-04-03 Emory University Anti-cd40 antibodies and uses thereof
US8911726B2 (en) 2004-09-22 2014-12-16 Kyowa Hakko Kirin Co., Ltd Stabilized human Igg4 antibodies
WO2016119909A1 (en) 2015-01-30 2016-08-04 Ucb Biopharma Sprl Treatment of autoimmune disorders with cd154 antibodies
WO2016126702A1 (en) 2015-02-03 2016-08-11 Als Therapy Development Institute Anti-cd40l antibodies and methods for treating cd40l-related diseases or disorders
US9475879B2 (en) 2011-04-21 2016-10-25 Bristol-Myers Squibb Company Antibody polypeptides that antagonize CD40
WO2017004006A1 (en) 2015-06-29 2017-01-05 Bristol-Myers Squibb Company Antibodies to cd40

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3737433A (en) 1964-09-05 1973-06-05 Albert Ag Chem Werke Certain oxoalkyldimethylxanthines
DE2819094A1 (de) 1977-05-10 1978-11-23 Sandoz Ag Cyclosporin-derivate, ihre verwendung und herstellung
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
FI65914C (fi) 1978-03-07 1984-08-10 Sandoz Ag Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a
EP0056782B1 (en) 1981-01-09 1984-08-01 Sandoz Ag Novel cyclosporins
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4576284A (en) 1983-12-02 1986-03-18 Warner-Lambert Company Closing of filled capsules
US4894366A (en) 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
CH667274A5 (de) 1984-03-23 1988-09-30 Sandoz Ag Cyclosporine, ihre herstellung und diese enthaltende pharmazeutische zusammensetzungen.
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DE3438830A1 (de) 1984-10-23 1986-04-30 Rentschler Arzneimittel Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
WO1987002671A1 (en) 1985-11-01 1987-05-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8611905D0 (en) 1986-05-15 1986-06-25 Lilly Industries Ltd Capsules
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
GB8729153D0 (en) 1987-12-14 1988-01-27 Efamol Ltd Fatty acid compositions
AU609242B2 (en) 1988-01-29 1991-04-26 Novartis Ag Cyclosporin compositions
HU201567B (en) 1988-07-21 1990-11-28 Gyogyszerkutato Intezet Process for production of intravenous medical compositions containing cyclosphorin
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3919982A1 (de) 1989-06-19 1990-12-20 Liedtke Pharmed Gmbh Orale lipidarzneiform
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
JPH04230389A (ja) 1990-07-16 1992-08-19 American Home Prod Corp ラパマイシン誘導体
US5023262A (en) 1990-08-14 1991-06-11 American Home Products Corporation Hydrogenated rapamycin derivatives
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
PT98990A (pt) 1990-09-19 1992-08-31 American Home Prod Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5100883A (en) 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5118678A (en) 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5118677A (en) 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
US5120727A (en) 1991-05-29 1992-06-09 American Home Products Corporation Rapamycin dimers
US5120725A (en) 1991-05-29 1992-06-09 American Home Products Corporation Bicyclic rapamycins
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5164495A (en) 1991-09-18 1992-11-17 Abbott Laboratories Method for preparing a dicarboxylic acid half-acid ester of FK506
ATE181571T1 (de) 1991-09-23 1999-07-15 Medical Res Council Methoden zur herstellung humanisierter antikörper
US5151413A (en) 1991-11-06 1992-09-29 American Home Products Corporation Rapamycin acetals as immunosuppressant and antifungal agents
GB9125660D0 (en) 1991-12-03 1992-01-29 Smithkline Beecham Plc Novel compound
US5177203A (en) 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
US5874082A (en) 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
ZA935112B (en) 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
US5234140A (en) 1992-07-28 1993-08-10 S. C. Johnson & Son, Inc. Re-useable aerosol container
US5256790A (en) 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
MX9305070A (es) 1992-08-21 1994-04-29 Genentech Inc Compocicion farmaceutica que contiene un antagonista de lfa-1 para el tratamiento de transtornos o desordenes mediados por el lfa-1
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5258389A (en) 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
KR960704576A (ko) 1993-10-01 1996-10-09 크리스토퍼 엘. 와이트 CD40에 대한 항체(Antibodies to CD40)
CA2175215C (en) 1993-11-19 2008-06-03 Yat Sun Or Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
US5908635A (en) 1994-08-05 1999-06-01 The United States Of America As Represented By The Department Of Health And Human Services Method for the liposomal delivery of nucleic acids
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US6096716A (en) 1994-12-12 2000-08-01 The Board Of Regents, The University Of Texas System Liposome-mediated transfection of central nervous system cells
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5827822A (en) 1996-03-25 1998-10-27 Sangstat Medical Corporation Cyclosporin a formulations as nanoparticles
US5766629A (en) 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
US20030099642A1 (en) 1996-04-22 2003-05-29 Michael J. Yellin Therapeutic applications for the anti-t-bam (cd40l) monoclonal antibody 5c8 in the treatment of vasculitis
WO1997022256A1 (en) 1995-12-19 1997-06-26 National Jewish Center For Immunology And Respiratory Medicine Method to regulate cd40 signaling
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
NZ513935A (en) 1999-02-17 2004-02-27 Csl Ltd Immunogenic complexes and methods relating thereto
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
CA2424296A1 (en) 2000-10-02 2002-04-11 Chiron Corporation Human anti-cd40 antibodies
US20040126829A1 (en) 2001-12-18 2004-07-01 Hildebrand William H. Anti-HLA assay and methods
ES2346978T3 (es) 2003-11-04 2010-10-22 Novartis Vaccines And Diagnostics, Inc. Uso de anticuerpos monoclonantes anti-cd40 antagonistas para el tratamiento del mieloma multiple.
CN101014620B (zh) 2004-02-06 2012-05-09 马萨诸塞州大学 抗艰难梭菌毒素抗体及其用途
AU2005333126A1 (en) 2004-07-18 2006-12-21 Csl Limited Methods and compositions for inducing innate immune responses
EP1781325A2 (en) 2004-07-18 2007-05-09 CSL Limited Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
US20060280738A1 (en) 2005-06-08 2006-12-14 Tedder Thomas F Anti-CD19 antibody therapy for transplantation
JP2009518441A (ja) * 2005-12-09 2009-05-07 シアトル ジェネティクス，インコーポレーテッド Ｃｄ４０結合剤の使用方法
EP1854810A1 (en) 2006-05-09 2007-11-14 PanGenetics B.V. Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
US10533054B2 (en) 2013-01-31 2020-01-14 Thomas Jefferson University Agonist fusion protein for CD40 and OX40 and methods of stimulating the immune system
WO2016199146A1 (en) 2015-06-09 2016-12-15 B. G. Negev Technologies And Applications Ltd A controlled release system for pulmonary delivery of surfactant protein d
JP6976931B2 (ja) 2015-09-04 2021-12-08 プリマトープ・セラピューティクス・インコーポレイテッド ヒト化抗ｃｄ４０抗体及びその使用

Patent Citations (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677165A (en) 1992-07-09 1997-10-14 Chiron Corporation Anti-CD40 monoclonal antibodies capable of blocking B-cell activation
US6280957B1 (en) 1998-02-04 2001-08-28 The General Hospital Corporation Costimulatory blockade and mixed chimerism in allo-transplantation
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
US20090311268A1 (en) 2000-02-01 2009-12-17 Pangenetics Bv Cd40-binding activating antibodies
US20020031512A1 (en) 2000-04-19 2002-03-14 M. C. Pasch CD40 antagonists for use in treating psoriasis and other inflammatory skin conditions
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
US7537763B2 (en) 2000-04-28 2009-05-26 Kyowa Hakko Kirin Co., Ltd. Anti-CD40 monoclonal antibody
WO2001098357A2 (en) 2000-06-19 2001-12-27 Beth Israel Deaconess Medical Center Compositions and methods of monoclonal and polyclonal antibodies specific for t cell subpopulations
EP1297017A2 (en) 2000-06-19 2003-04-02 Beth Israel Deaconess Medical Center Compositions and methods of monoclonal and polyclonal antibodies specific for t cell subpopulations
US20100234578A1 (en) 2001-04-27 2010-09-16 Kyowa Hakko Kirin Co., Ltd. Anti-cd40 monoclonal antibody
US7193064B2 (en) 2001-04-27 2007-03-20 Kirin Beer Kabushiki Kaisha Anti-CD40 monoclonal antibody
US20100098694A1 (en) 2001-11-09 2010-04-22 Amgen Fremont Inc. Antibodies to cd40
US20070190051A1 (en) 2001-11-09 2007-08-16 Abgenix, Inc. Antibodies to CD40
WO2003040170A2 (en) 2001-11-09 2003-05-15 Pfizer Products Inc. Antibodies to cd40
US20030211100A1 (en) 2001-11-09 2003-11-13 Vahe Bedian Antibodies to CD40
JP2005508176A (ja) 2001-11-09 2005-03-31 ファイザー・プロダクツ・インク Ｃｄ４０に対する抗体
US20040110226A1 (en) 2002-03-01 2004-06-10 Xencor Antibody optimization
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
JP2007513073A (ja) 2003-11-04 2007-05-24 カイロン コーポレイション Ｂ細胞に関連する癌に対する治療方法
US20070110754A1 (en) 2003-11-04 2007-05-17 Chiron Corporation Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia
EP1682180A2 (en) 2003-11-04 2006-07-26 Chiron Corporation Antagonist anti-cd40 monoclonal antibodies and methods for their use
WO2005044307A2 (en) 2003-11-04 2005-05-19 Chiron Corporation Methods of therapy for b cell-related cancers
WO2005044854A2 (en) 2003-11-04 2005-05-19 Chiron Corporation Antagonist anti-cd40 monoclonal antibodies and methods for their use
EP1707627B1 (en) 2003-12-25 2012-11-14 Kyowa Hakko Kirin Co., Ltd. Antagonistic anti-CD40 antibody mutant
US9023360B2 (en) 2003-12-25 2015-05-05 Kyowa Hakko Kirin Co., Ltd. Methods of treating autoimmune disease with anti-CD40 antibodies
US9023361B2 (en) 2003-12-25 2015-05-05 Kyowa Hakko Kirin Co., Ltd. Methods for treating transplant rejection by administering anti-CD40 antibody
US9598494B2 (en) 2003-12-25 2017-03-21 Kyowa Hakko Kirin Co., Ltd. Anti-CD40 antibody mutants
US8106164B2 (en) 2004-06-21 2012-01-31 Bioarctic Neuroscience Ab Antibodies specific for soluble amyloid beta peptide protofibrils and uses thereof
US8911726B2 (en) 2004-09-22 2014-12-16 Kyowa Hakko Kirin Co., Ltd Stabilized human Igg4 antibodies
US8226952B2 (en) 2005-02-02 2012-07-24 University Of Massachusetts Human antibodies against rabies and uses thereof
US8303955B2 (en) 2005-05-26 2012-11-06 Seattle Genetics, Inc. Humanized anti-CD40 antibodies and their methods of use
WO2007053767A1 (en) 2005-11-01 2007-05-10 Novartis Ag Uses of anti-cd40 antibodies
JP2009513712A (ja) 2005-11-01 2009-04-02 ノバルティス アーゲー 抗ｃｄ４０抗体の使用
EP1945260A1 (en) 2005-11-01 2008-07-23 Novartis AG Uses of anti-cd40 antibodies
WO2007053661A2 (en) 2005-11-01 2007-05-10 Novartis Ag Uses of anti-cd40 antibodies
US20090304706A1 (en) 2006-04-21 2009-12-10 Novartis Ag Antagonist anti-cd40 antibody pharmaceutical compositions
US8138134B2 (en) 2006-09-29 2012-03-20 Union Carbide Chemicals & Plastics Technology Llc Quaternized cellulose ethers for personal care products
US8784823B2 (en) 2007-03-22 2014-07-22 Biogen Idec Ma Inc. Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind CD154 and uses thereof
WO2008118356A2 (en) 2007-03-22 2008-10-02 Biogen Idec Ma Inc. Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
JP2011503098A (ja) 2007-11-09 2011-01-27 ノバルティス アーゲー 抗ｃｄ４０抗体の使用
WO2009062054A1 (en) 2007-11-09 2009-05-14 Novartis Ag Uses of anti-cd40 antibodies
US20110027276A1 (en) 2008-01-23 2011-02-03 Xencor ,Inc. Optimized CD40 Antibodies and Methods of Using the Same
WO2010065819A1 (en) 2008-12-05 2010-06-10 Als Therapy Development Institute Method for the treatment of neurodegenerative diseases
US8435514B2 (en) 2008-12-05 2013-05-07 Als Therapy Development Institute Method for the treatment of neurodegenerative diseases
US20100239575A1 (en) 2009-03-10 2010-09-23 Baylor Research Institute Anti-cd40 antibodies and uses thereof
US8591900B2 (en) 2010-03-31 2013-11-26 Boehringer Ingelheim International Gmbh Anti-CD40 antibodies
US20110243932A1 (en) 2010-03-31 2011-10-06 Boehringer Ingelheim International Gmbh Anti-cd40 antibodies
WO2012065950A1 (en) 2010-11-15 2012-05-24 Novartis Ag Silent fc variants of anti-cd40 antibodies
WO2012111762A1 (ja) 2011-02-17 2012-08-23 協和発酵キリン株式会社 抗ｃｄ４０抗体の高濃度製剤
US9125893B2 (en) 2011-02-17 2015-09-08 Kyowa Hakko Kirin Co., Ltd. Highly concentrated anti-CD40 antibody pharmaceutical preparation
US20140093497A1 (en) 2011-03-11 2014-04-03 Emory University Anti-cd40 antibodies and uses thereof
US9475879B2 (en) 2011-04-21 2016-10-25 Bristol-Myers Squibb Company Antibody polypeptides that antagonize CD40
WO2016119909A1 (en) 2015-01-30 2016-08-04 Ucb Biopharma Sprl Treatment of autoimmune disorders with cd154 antibodies
WO2016126702A1 (en) 2015-02-03 2016-08-11 Als Therapy Development Institute Anti-cd40l antibodies and methods for treating cd40l-related diseases or disorders
WO2017004006A1 (en) 2015-06-29 2017-01-05 Bristol-Myers Squibb Company Antibodies to cd40

Non-Patent Citations (58)

* Cited by examiner, † Cited by third party
Title
Adams, Development of a Chimeric Anti-CD40 Monoclonal Antibody That Synergizes with LEA29Y to prolong Islet Allograft Survival, J Immunol 2005; 17 4(1):542-50.
Albach, et al., "Safety, pharmacokinetics and pharmacodynamics of single rising doses of BI 655064, an antagonistic anti-CD40 antibody in healthy subjects: a potential novel treatment for autoimmune diseases," Eur J Clin Pharmacol, 9 pages.
Aoyagi et al., "A Human Anti-CD40 Monoclonal Antibody, 4D11, for Kidney Transplantation in Cynomolgus Monkeys: Induction and Maintenance Therapy," American Journal Transplantation 2009; 9: 1732-1741.
Apexigen APX005M Briefing Materials, Oncologic Drugs Advisory Committee, Jun. 21, 2017; 22 pages.
Badell, et al. "Non-Depleting Anti-CD40-Based Therapy Prolongs Allograft Survival in Nonhuman Primates," Am. J. Transplant, 2012, 12(1):126-135.
Bankert et al., "Induction of an Altered CD40 Signaling Complex by an Antagonistic Human Monoclonal Antibody to CD49" The Journal of Immunology 2015; 194:4319-4327.
Boon et al., "Preclinical assessment of anti-CD40 Mab 5D12 cynomolgus monkeys," Toxicology. 174(1):53-65 (2002).
Boon et al., "Prevention of experimental autoimmune encephalomyelitis in the common marmoset (Callithrix jacchus) using a chimeric antagonist monoclonal antibody against human CD40 is associated with altered B cell responses," J Immunol. 167(5):2924-9 (2001).
C. Schwabe, et al., "FRI0168 Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BI 655064, An Antagonistic Anti-CD40 Antibody in Healthy Volunteers," BMJ Journals, vol. 74, Issue Suppl 2, 3 pages.
Carpenter, et al. Activation of human B cells by the agonist CD 40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation, Journal of Translational Medicine 2009, 7:93; 10 pages.
Chamberlain C, et al., "Repeated administration of dapirolizumab pegol in a radomised phase I study is well tolerated and accompanied by improvements in several disease activity and changes in whole blood transcriptomic profiles," Ann Rheum Dis 2017; 0:1-8; 9 pages.
Chen et al., EMBO J., 14: 2784-2794 (1995).
Colman, Research in Immunology 145:33-36 (1994).
Communication and substantive Office Action for European Patent Application No. 12758099.1 dated Dec. 22, 2016, 7 pages.
Communication for European Application No. 12758099.1-412, dated Aug. 26, 2014 (3 pages).
Cooper et al., "Platelet-associated antibodies, cellular immunity and FCGR3A genotype influence the response to rituximab in immune thrombocytopenia," British Journal of Haematology, 2012, 158 , 539-547.
Cordoba, et al., "A Novel, Blocking, Fc-Silent Anti-CD40 Monoclonal Antibody Prolongs Nonhuman Primate Renal Allograft Survival in the Absence of B Cell Depletion," American Journal of Tranplantation 2015; 15: 2825-2836.
de Boer et al., "Generation of monoclonal antibodies to human lymphocyte cell surface antigens using insect cells expressing recombinant proteins," J Immunol Methods. 152(1) :15-23 (1992).
Denton et al., "Central role for CD40/CD40 ligand (CD154) interactions in transplant rejection," Pediatr Transplant. 2 (1):6-15 (1998). Abstract Only. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/10084754> on Nov. 18, 2013.
Final Rejection for Japanese Application No. 2013-557941, dated Mar. 7, 2017 (10 pages).
First Examination Report for Australian Patent Application No. 2012229236, dated May 4, 2016 (4 pages).
Gershoni et al., "Epitope mapping-the first step in developing epitope-based vaccined," BioDrugs. 21(3): 145-56 (2007).
Gershoni et al., "Epitope mapping—the first step in developing epitope-based vaccined," BioDrugs. 21(3): 145-56 (2007).
Gilson et al., "Anti-CD40 monoclonal antibody synergizes with CTLA4-lg in promoting longterm graft survival in murine models of transplantation," J Immunol. 183(3): 1625-35 (2009).
Grammer et al, "Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions." The Journal of Clinical Investigation, Nov. 2003, vol. 112, No. 10, pp. 1506-1520.
Haanstra et al., "Prevention of Kindney allograft rejection using anti-CD40 and anti-CD86 in primates." Transplantation. 75(5):637-43 (2003).
International Search Report and Written Opinion dated Jan. 19, 2017 corresponding to International Patent Application PCT/US16/50114; 14 pages.
International Search Report and Written Opinion for International Application No. PCT/US2012/028782, dated Sep. 14, 2012 (11 pages).
Kim et al., "Costimulation blockade alters germinal center responses and prevents antibody-medicated rejection." Am J Transplanr. Jan. 2014; 14(1): 59-69.
Kim et al., Fc-Silent Anti-CD154 Domain Antibody Effectively Prevents Nonhuman Primate Renal Allograft Rejection. American Journal of Transplantation 2017; 17: 1182-1192, Wiley Periodicals Inc.
Kussie et al., J. Immunol. 152: 146-152 (1994).
Kuwana et al, Effect of a single injection of humanized anti-CD154 monoclonal antibody on the platelet-specific autoimmune response in patients with immune thromocytopenic purpura, Blood, Feb. 15, 2004, vol. 103, No. 4; 1229-1236.
Liu et al., "Agonistic antibody to CD40 boosts the antitumor activity of adoptively transferred T cells in vivo," 35(3): 276-82 (2012).
Lowe et al., "A Novel Monoclonal Antibody to CD40 Prolongs Islet Allograft Survival,"Am J. Transplant, Aug. 2012; 12(8): 2079-2087.
Luqman et al., "The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells," Blood. 112(3):711-20 (2008).
Modiuddin, et al., "Chimeric 2C10R4 anti-CD40 antibody therapy is critical for long-term survival of GTKO.hCD46.h TBM pig-to-primate cardiac xenograft," Nature Communications, pp. 1-10.
Molano et al., "Prolonged islet allograft survival in diabetic NOD mice by targeting CD45RB and CD154," Diabetes. 52(4):957-64 (2003).
Morris, Epitope mapping of protein antigens by competition ELISA. The Protein Protocols Handbook. Humana Press, 595-600 (1996).
Najafian et al., "CTLA4-Ig: a novel immunosuppressive agent," Expert Opin Investig Drugs. 9(9):2147-57 (2000).
Office Action for Chinese Application No. 201280022277.3, dated Aug. 25, 2014 (19 pages).
Office Action for Japanese Application No. 2013-557941, dated Jul. 26, 2016 (16 pages).
Office Action for Japanese Application No. 2013-557941, dated Oct. 27, 2015 (16 pages).
Okimura, et al. Characterization of ASKP1240, a Fully Human Antibody Targeting Human CD40 With Potent Immunosuppressive Effects, American Journal of Transplantation 2014; 14: 1290-1299.
O'Neill, et al. Comparative Evaluation of aCD40 (2C10R4) and aCD154 (5c8h1 and IDEC-131) in a Nonhuman Primate Cardiac Allotransplant Model. Transplantation. 101(9):2038-2047, 2017.
Oura et al., "Long-term hepatic allograft acceptance based on CD40 blockade by ASKP1240 in nonhuman primates," Am J Transplant. 12(7):1740-54 (2012).
Pearson et al., "Anti-CD40 therapy extends renal allograft survival in rhesus macaques," Transplantation. 7 4(7): 933-40 (2002).
Rudikoff et al., Proc Natl Acad Sci USA 79: 1979-1983 (1982).
Russo et al., "Platelet-activating factor mediates CD40-dependent angiogenesis and endothelial-smooth muscle cell interaction," J Immunol. 171 (10):5489-97 (2003).
S. Daniluk, et al., "SAT0147 Safety and Efficacy of BI 655064, An Antagonistic Anti-CD40 Antibody in Rheumatoid Arthritis (RA) Patients," BMJ Journals, vol. 75, Issue Suppl 2, 3 pages.
S. Visvanathan, et al., "FRI0231 Trearment with BI 655064, (Antagonistic Anti-CD40 Antibody) Modulates Biomarkers Associated with Rheumatoid Arthritis (RA)," BMJ Journals, vol. 75, Issue Suppl 2, 3 pages.
S. Visvanathan, et al., Treatment with BI 655064 (Antagonistic Anti-CD40 Antibody) Modulated Biomarkers Associated with Rheumatoid Arthritis (RA), Scientific Abstracts, Jun. 10, 2016; p. 517.
Sho et al., "Requirements for induction and maintenance of peripheral tolerance in stringent allograft models," Proc Natl Acad Sci USA 102(37): 13230-5 (2005).
Shock, et al., "CDP7657, an anti0CD40L antibody lacking and Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study." Arthritis Research & Therapy (2015) 17:234; pp. 1-12.
Slade, et al., "Assessment of Safety, Pharmacokinetics and Pharmacodynamics of a Novel Anti-CD40 Monoclonal Antibody, CFZ533, in Healthy Volunteers and in Rheumatoid Arthritis Patients," 2016 ACR/ARHP Annual Meeting, Sep. 2016, Abstract No. 1582, 2 pages.
Strohl, "Optimization of Fc-mediated effector functions of monoclonal antibodies," Curr Opin Biotechnol. 20(6):685-91 (2009).
Sutherland et al., "Anti-CD45RB antibody deters xenograft rejection by modulating T cell priming and homing," Int Immunol. (8):953-62 (2002).
Thompson et al., "CD40-specific costimulation blockade enhances neonatal porcine islet survival in nonhuman primates," Am J Transplant. 11 (5):947-57 (2011).
Yamniuk, et al. "Functional Antagonism of Human CD40 Achieved by Targeting a Unique Species-Specific Epitope," J. Mol. Biol., 2016, 428: 2860-2879.

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10561728B2 (en) 2011-03-11 2020-02-18 Beth Israel Deaconess Medical Center, Inc. Polynucleotides encoding anti-CD40 antibodies
US10201608B2 (en) * 2015-09-04 2019-02-12 Primatope Therapeutics Inc. Polynucleotides encoding humanized anti-CD40 antibodies
US10772958B2 (en) 2015-09-04 2020-09-15 Primatope Therapeutics Inc. Humanized anti-CD40 antibodies and methods of administering thereof
US11439706B2 (en) 2015-09-04 2022-09-13 Primatope Therapeutics Inc. Polynucleotides encoding a humanized anti-CD40 antibody
US11396552B2 (en) 2018-02-12 2022-07-26 Diabetes-Free Inc. Antagonistic anti-human CD40 monoclonal antibodies

Also Published As

Publication number Publication date
CN109069621A (zh) 2018-12-21
US11439706B2 (en) 2022-09-13
CN109069621B (zh) 2022-09-06
JP2021168685A (ja) 2021-10-28
AU2016315873A1 (en) 2018-04-12
EP3307322A1 (en) 2018-04-18
KR20180044422A (ko) 2018-05-02
WO2017040932A1 (en) 2017-03-09
US20190117771A1 (en) 2019-04-25
EP3906943A1 (en) 2021-11-10
PT3307322T (pt) 2021-04-23
EP3307322A4 (en) 2018-05-30
EP3307322B1 (en) 2021-02-17
PL3307322T3 (pl) 2021-07-05
AU2022241635A1 (en) 2022-11-03
MX2022015631A (es) 2023-01-11
US20200384107A1 (en) 2020-12-10
MX2018002708A (es) 2018-08-01
CA3002789A1 (en) 2017-03-09
ES2887602T3 (es) 2021-12-23
JP2018531591A (ja) 2018-11-01
AU2016315873B2 (en) 2022-08-18
US10201608B2 (en) 2019-02-12
JP6976931B2 (ja) 2021-12-08
US20220387587A1 (en) 2022-12-08
DK3307322T3 (da) 2021-04-19
CN116063481A (zh) 2023-05-05
US10772958B2 (en) 2020-09-15
JP2023103460A (ja) 2023-07-26
BR112018004296B1 (pt) 2020-05-05
US20180078640A1 (en) 2018-03-22
HK1251974A1 (zh) 2019-05-10
US20180280507A1 (en) 2018-10-04
SI3307322T1 (sl) 2021-08-31
HUE056769T2 (hu) 2022-03-28

Similar Documents

Publication Publication Date Title
US11439706B2 (en) Polynucleotides encoding a humanized anti-CD40 antibody
AU2019246821B2 (en) Anti-cd40 antibodies and uses thereof

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.)

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL)

AS Assignment

Owner name: PRIMATOPE THERAPEUTICS INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:YU, BO;WANG, RIJIAN;REIMANN, KEITH;SIGNING DATES FROM 20151003 TO 20151111;REEL/FRAME:045554/0191

STCF Information on status: patent grant

Free format text: PATENTED CASE

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2551); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

Year of fee payment: 4